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ABSTRACT 
Introduction 
A retrospective study of deaths attributable to anaphylaxis at the Salt River Forensic 
Pathology Laboratory was undertaken, with a view to determine if eosinophilia was 
present in tissue samples of the spleen, in accordance with previously published 
research.  Suitable cases of non-anaphylactic death were used as controls. Use was 
made of two commonly available fabric dyes as alternative stains to the traditional 
Haematoxylin –Eosin [“H&E”]. 
Methods 
Use was made of two common fabric dyes, as stains to visualise eosinophils, one 
local, cheap and readily available, sold as MagentaTM, the other sold as Pagoda Red 
TM and manufactured by DYLON TM, also relatively cheap but locally unavailable.  
H&E stain was used as a control. 
Simultaneously the study sought to determine if post-mortem mast cell tryptase 
levels were a reliable diagnostic indicator of anaphylactic death. 
5µm sections of splenic tissue from samples and controls were stained using each of 
the three stains, and eosinophils were counted in 10 randomly selected 40x fields. 
Cell counts were performed by an experienced analyst and an inexperienced 
analyst. Cell counts were statistically analysed using the Wilcoxon rank-sum method 
to determine statistically significant differences between cell counts. Spearman 
correlation co-efficients were used to determine if a significant correlation existed 
between cell counts and mast cell tryptase levels. 
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Results  
Statistical analysis of the results demonstrated the following: 
- There was no statistically significant difference in eosinophil counts between 
anaphylactic death cases and control cases at the p < 0.05 level, thus 
negating previous research which postulated the spleen as a shock organ 
accumulating eosinophils in cases of anaphylaxis. 
 
- Secondly, there was no statistically significant difference in eosinophil counts 
between the various stains used, but subjectively the use of Pagoda Red dye 
rendered eosinophils more easily visible, and resulted in a reduced amount of 
time being spent in counting them. This is of significance in a resource 
challenged environment with a heavy forensic autopsy load. 
 
 
- Lastly, there was no significant difference [p<0.05] between the mast cell 




A retrospective study like this one has inherent limitations, such as dependency on 
previous data collection, laboratory test results being available and appropriate 
histology samples being obtainable.  Our test and control sample cohorts were small 
given the relatively few cases which fitted inclusion criteria:  i.e. full hard copy 
documentation, mast cell tryptase level and spleen section. 
Nonetheless, using the limited population at our disposal we can show that the use 
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of an alternative stain to H&E reduces the time spent in cell counts, and allows rapid 
differentiation between eosinophils and mast cells, as a result of enhanced 
visualisation.  Time saved is always welcome in busy work schedules.  Money saved 
through the use of a cheaper stain is an obvious benefit  
Further research is necessary into the use of other, possibly more appropriate, dyes 
as the dyes selected would appear to be composite in nature.  The identification of 
the major component in each dye may thus identify a dye that will prove to be a 
cheap, locally available alternative. 
 
The lack of correlation between mast cell tryptase levels and eosinophil counts 
warrants further extensive research, using a larger, multi-centre sample population. 
 
Therefore, although this research project innocuously set out to verify the usefulness 
of fabric dyes to easily and readily visualize eosinophils in splenic tissue, the 
analysis of the results has shown it to be a veritable hornet’s nest of controversy in 
the area of post-mortem diagnosis of anaphylaxis, and in the involvement of several 
different organs.  Further extensive research is deemed necessary to address these 




In order not to burden this document with a papery sump of repetitive references, the 
references have been divided into two sections. Those utilized in the Research 
Proposal and Literature Survey is reflected in the Appendices.   
 
In respect of the Journal article for publication, the references are found immediately 
after the conclusions, as for publication it is expected that the relevant references 
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appear here. In addition the convention specified by the journal is numeric in nature 
hence the UCT-Harvard method is not used here. 
 
It being impossible to include the high resolution photomicrographs in the body of 
this document, a complete set of photomicrographs is available, on request, on CD-
ROM. 
Similarly, should copies of the actual spreadsheets be required these are also 
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SECTION A:  RESEARCH PROPOSAL 
 
Title:  An investigation into the use of a commonly available fabric dye as a routine 
stain for tissue samples to be used as a first line, low cost, diagnostic adjunct 
for the diagnosis of anaphylactic death at autopsy, in a resource-challenged 
environment. 
 
Principal investigators:   P.J. Burgers; Dr. L Liebenberg [supervisor]; Department 
of  Clinical Laboratory Sciences; Division of Forensic 
Medicine , University of Cape Town  Health Sciences 
Faculty 
Co-investigators:  Ms. M. Perrins; Chief Medical Technologist; Ms. Y. Davis; 
Senior Medical Technologist; Department of Clinical 
Laboratory Sciences; Division of Forensic Medicine, 
University of Cape Town Health Sciences Faculty 
Introduction 
 
Anaphylaxis is widely recognised as the most dangerous response the body offers to 
challenge by a variety of allergens, and in doses that often bear no relation to the 
severity and speed of onset of the reaction (Scarlet, 2006). 
It is characterised as a systemic reaction with an acute response varying in time from 
seconds to minutes after challenge. 
Generally it is a reaction that can involve a multiplicity of body systems, is very often 
unpredictable, characterised by rapid onset, and can have fatal, alternatively life–
threatening consequences in serious cases. 
If the reaction is as a result of an antigen/antibody response and commonly involving 
Immunoglobulin E [IgE] with a subsequent widespread activation of mast cells and 
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the release of various cytokines, the reaction is termed an anaphylactic reaction. 
If, however, the reaction follows in consequence of a non-antibody trigger [and is 
thus non-IgE mediated], the reaction is termed anaphylactoid, and is generally and 
clinically indistinguishable from anaphylaxis.(Walther & Bottiger, 2004; Ring, 
Behrendt & de Weck, 2010) 
Despite this difference the management and treatment of both reactions is the same. 
Often the response is fatal and deaths due to anaphylaxis may be due to acute 
respiratory distress, consequent on glottal œdema, bronchial obstruction or 
bronchospasm; alternatively due to cardiovascular collapse. 
Owing to the non-specificity of symptoms, the determination of anaphylaxis 
[alternatively an anaphylactoid reaction] as the cause of death at autopsy is one 
fraught with problems. Determination of the cause of death may well revolve on a 
differential diagnosis, or an exclusion of other causes. 
As a result, in cases of suspected anaphylactic /anaphylactoid death scrupulous 
attention to detail at autopsy is necessary; a full history is virtually obligatory, coupled 
with a complete autopsy. Histological and immunohistochemical testing can 
significantly aid the diagnosis, as can biochemical testing for mast cell tryptase 
[“MCT”], total IgE level and sometimes specific antigen IgE level. 
Routine histology may be unhelpful, and immunohistochemical and biochemical 
testing is expensive.  Autopsy findings alone are thus often non-specific.   
 
Laboratory testing in the form of mast cell specific immunohistochemical testing as 
well as the determination of mast cell tryptase levels, and routine biochemical testing 
are useful as diagnostic adjuncts, however conflicting results have been obtained 
[Schwarz 2006].   
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Furthermore, in the case of mast cell tryptase, serial testing is required, with a 
baseline level determined, during 1st hour of presentation and then 24 hours later.  
Such baseline or ante-mortem level is seldom available in autopsy cases.   
Cost of testing is a significant factor. Written quotes obtained in 2015 for biochemical 
testing were determined as follows:  Multiple specific Antigen IgE ZAR 279.92; 
Combined Antigen Specific IgE ZAR 183.76 [written quote, National Health 
Laboratory Services, price list 2015:], 
What seems to be required is a simple, low-cost, first line diagnostic tool which will 
support or negate an initial diagnosis of anaphylactic/anaphylactoid death, which 
may then be followed up by more sophisticated tests [such as immunohistochemical 
tests] if deemed necessary. 
Such a diagnostic aid would have to be simple in nature, easily performed and use 
readily available materials, particularly in an environment that is resource-
challenged.  A study of the literature has shown that in certain instances a commonly 
available fabric dye, manufactured by the company DYLON and sold as Pagoda Red 
TM can be successfully used to demonstrate eosinophilia and mast cell degranulation 
in stained histological slides of splenic tissue. This published research supports a 
theory that mast cell degranulation and hypereosinophilia particularly in splenic 
tissue and possibly in lung and liver tissue is indicative, and possibly pathognomonic, 
of anaphylactic/anaphylactoid death. (Trani et al., 2008; Reggiani Bonetti et al., 
2014) 
Although the dye does not differentiate between mast cells and eosinophils, the 
presence of mast cells, increased numbers of eosinophils and mast cell granules in 
the spleen would thus appear to be a valuable aid in supporting a diagnosis of 
P a g e  | 13 
anaphylactic death. 
 
Preliminary investigations have shown that the particular shade of dye, Pagoda Red 
used in the overseas studies mentioned below is not readily available in South 
Africa.  Reference to previously published research indicated that perhaps other 
dyes would be equally successful (Kiyono et al., 1982; Yanagihara, Mehregan & 
Mehregan, 1984).  Hence this study will attempt to determine if the use of a dye 
colour [Lady Dye “Magenta” TM] commonly available at retail pharmacies in the Cape 
Town area] will consistently reproduce the results shown by overseas researchers 
(Trani et al., 2008; Edston, 2013; Reggiani Bonetti et al., 2014). 
 
In examining this problem the original dyestuff, Pagoda Red will be used to prepare 
samples for comparative study.  As the study seeks to replicate results obtained and 
published (Trani et al., 2008; Edston, 2013), it was not deemed necessary to incur 
the expense of immunohistochemical staining as confirmation of the histological 
results.  Nonetheless, attempts were made to determine if the appropriate and 
specific immunohistochemical staining could be performed locally.  This proved not 
to be the case, as the closest appropriate stain was CD 117 at a cost of ZAR 900.00 
per slide as against a cost of ZAR75.00 for the dye-stained slides [written quote, 
National Health Laboratory Services, 26 August 2014]. 
Methods 
 
This will be a retrospective study of tissue samples retained at autopsy in confirmed 
anaphylactic deaths at Salt River Forensic Pathology Laboratory. A retrospective 
study has inherent limitations.  The very fact that it is retrospective implies that fresh 
sampling cannot be performed, additional samples are unavailable, the autopsy 
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cannot be “redone”, and most significantly the methodology and reasoning  of the 
pathologists involved may not be open to discussion they having left the employ of 
the Department.  
Selection criteria for both test and control cases will be:  
(a) MCT level as obtained from a spreadsheet record of tests performed for 
forensic pathology by the Lung Institute of UCT.  Forensic Pathology Case 
numbers and mast cell tryptase level are recorded.  This is the start off point 
of case selection. 
 
(b) For cases where MCT results are available, full autopsy documentation 
including police information and medical records where available will be 
retrieved from the UCT Division of Forensic Medicine’s archive. 
 
 
(c) From documentation it will be established whether tissue samples were 
retained for histological examination 
 
(d) Full histological slide collections will be examined and it will be determined 
whether spleen section was done. A splenic sample for histological sectioning 
and staining, according to published protocol is necessary 
 
 
(e) A diagnosis of anaphylactic  versus non anaphylactic death  cases will be 
identified by a senior pathologist by studying the full case records from the 
archive and special investigations including the full histological slide 
collection.  
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In amplification of the above, the diagnosis of anaphylaxis for the study samples 
should be in strict accordance with the protocols of Forensic Pathology Services.  
That is a full autopsy, tissue samples from all internal organs as per the standard 
operating protocol, full histological examination, coupled with a review of 
contemporaneous notes and the exclusion of other causes of death, followed by 
review by a senior pathologist. The presence of hospital records is regarded as a 
useful adjunct, but is often not available. Succinctly stated it should be a reasoned 
well researched differential diagnostic process to either include or exclude 
anaphylactic death. 
 
In the case of the control samples, should sufficient samples be found that satisfy the 
initial criteria of Mast Cell Tryptase level, and spleen tissue samples, the records will 
then be examined in accordance with the protocol above to determine if anaphylaxis 
has been positively excluded. 
 
The inclusion of an available MCT levels as a criterion is based on the literature 
which in earlier times supported a diagnosis of anaphylactic death, but not as a “gold 
standard. Randall Butts & Halsey (Randall, Butts & Halsey, 1995) showed that an 
appropriate clinical history together with an elevated MCT level and an allergen 
specific IgE level would be strong evidence of an anaphylactic death.  It must 
however be noted that elevated tryptase levels  may also occur in traumatic deaths, 
in particular those involving chest trauma, possibly as a result of mast cell lysis 
followed by degranulation 
 
In the case of the control samples, the diagnosis of death must exclude anaphylaxis 
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and similarly, be confirmed by a senior forensic pathologist. 
 
In order to validate the results negative controls comprising splenic tissue sections 
from confirmed non-anaphylactic deaths of the same age range and gender will be 
used.  The tissue samples used in the study, as well as negative controls will be 
sourced from the registered Forensic Pathology Tissue data bank.  The diagnosis for 
the control samples will be according to the protocol set out above; that is strict 
compliance with the standard protocols of Forensic Pathology Services, but with the 
difference that the diagnosis must positively exclude anaphylaxis as a cause of 
death 
 
Samples of spleen tissue will be sectioned and stained according to the method laid 
out by Trani et al. [2008] using firstly, imported Pagoda Red dye as the stain, in 
accordance with the method set out below, thereafter using Magenta dye, and H&E 
as a control stain. 
Briefly the paraffin tissue sections are floated in water, stained at 55 °Celsius for one 
hour in Pagoda Red stain comprising a 1 % aqueous solution of the dyestuff.  
Thereafter they are washed, counterstained with hæmatoxylin for 3 minutes, washed 
in tap water, dehydrated in alcohol, cleared in Xylene and then mounted for 
examination. 
The same process will then be repeated using the Lady Dye “Magenta “ as the stain;  
both samples will then be examined microscopically to determine if eosinophils, mast 
cells and mast cell granules are readily visible as reported by Trani et al [2008]. 
It is theorised that the use of the locally available stain, Magenta while being capable 
of staining mast cells, eosinophils and granules, will demonstrate a significant 
difference in colour/hue of the stained eosinophils when compared to stained slides 
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using H&E and Pagoda Red, as the local dye Magenta exhibits a markedly different 
pH characteristic when compared to the imported dyestuff Pagoda Red, and possibly 
a different structure. 
Study population and sampling 
 
The study population comprises all traceable cases of death due to anaphylaxis at 
Salt River Mortuary over the period 2002 to date.  At this point it is unknown exactly 
how many cases are on record. A search of the Department’s records together with 
archived “hard copy” documents will yield the numbers and diagnoses, thereby 
providing both samples and negative controls. 
Sampling. 
 
Sampling will be of spleen tissue retained at autopsy, and preserved in formalin or 
alternatively in paraffin wax embedded cassettes for histological examination as an 
aid to determining the cause of death. 
It is hoped that a sufficient number of cases will be available for a statistically valid 




The measurement criterion is that of Trani et al (2008): …“a diffuse perifollicular, 
cordonal and endosinusal splenic eosinophilia” determined by microscopy, coupled 
with Edston’s [2013] numeric criterion of more than 10 eosinophils per 40x field. . 
Eosinophils, mast cells and granules should, in accordance with Trani et al. and 
Edston’s reports [op.cit.] be readily visible as bright red on a pale blue background.  
We suspect, as stated above that the use of the local dye will give a similar, but not 
exactly the same, result:  i.e. the cells will still be stained but their relative contrast 
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against the blue background and the intensity of the colour produced may well be 
different. 
Pilot studies 
New sections of splenic tissue previously stained with H&E stain will be stained 
according to the protocol of Trani et al. [2008] with Lady Dye “Magenta”, and with 
Pagoda Red respectively.  All three slides will [i.e. the H&E, Magenta & Pagoda Red 




A sufficient quantity of “Magenta” dye has already been procured. 
A sufficient quantity [30 g equating to 3 litres of made-up stain] of Pagoda Red dye 
has been purchased in Canada and imported. 
In addition thereto, 30 g of recently manufactured Pagoda Red was donated by the 
manufacturer Spotless Punch plc., to be used in the study. 
The Division of Forensic Medicine and Toxicology of UCT has the necessary infra-
structure to process tissue sections and stain the selected sections. 
Budget 
This study is envisaged as costing, in total, no more than ZAR6000.00 made up as 
follows: 
Lady Dye Magenta dye 30g  R 100.00 
Dylon Pagoda Red dye 30g  R500.00 
Cost of slide preparation 50 slides at R100.00 per slide R5000.00 
TOTAL R5600.00 
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Ethical and legal considerations 
 
The envisaged study is a retrospective study using archived autopsy documents, 
historic mast cell tryptase results and tissue samples retained at autopsy in terms of 
Section 3(2) read with Section 3(3) of the Inquests Act No. 58 of 1959 of South 
Africa as amended, for the determination of cause of death. 
Anonymity of the persons from whom the tissue was retained is guaranteed as the 
researcher will use only the Forensic Pathology Service reference number allocated 
to the body at the time of autopsy [ e.g. WC/11/1234/xxxx], where xxxx indicates the 
relevant year in which the autopsy was performed. In cases selected prior to 
September 2006 the reference number follows the format DR xxxx/ YYYY, where 
xxxx represents the sequential number allocated, and YYYY represents the year in 
which the autopsy was performed. 
The outcome of the research is independent of, and will not in any way influence any 
past, current or future legal proceedings of any “ open inquest”, should the samples 
later prove to be from an “open inquest “ case. 
No other ethical or legal problems were identified.  
 
Reporting of results 
As the determination of success in using the alternative dye rests on visual 
comparisons with the Pagoda Red dye, it is envisaged that the results will be 
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SECTION B: LITERATURE SURVEY 
 
Title:   An investigation into the use of a commonly available fabric dye as a routine 
stain for tissue samples to be used as a first line, low cost, diagnostic adjunct 
for the diagnosis of anaphylactic death at autopsy, in a resource-challenged 
environment. 
 
Principal investigators:  P.J. Burgers; Dr. L Liebenberg [supervisor]; Department 
of  Clinical Laboratory Sciences; Division of Forensic 
Medicine , University of Cape Town  Health Sciences 
Faculty 
 
Co-investigators: Ms M. Perrins: Chief Medical Technologist; Ms Y. Davis: 
Senior Medical Technologist; Department of Clinical 
Laboratory Sciences; Division of Forensic Medicine, 





Anaphylaxis has been defined as the most dramatic and potentially catastrophic 
manifestation of immediate hypersensitivity.  The term   “Anaphylaxis” is derived 
from the Greek [ανά - against; φύλαξις - protection] (Bochner & Lichtenstein, 1991).  
In addition thereto the diagnosis of this oft deadly disease state presents unique and 
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challenging problems, ascribable not only to the multiplicity of symptoms it can 
present with, but also to the paucity of diagnostic tools that are disease specific.  To 
paraphrase Knight, the “feeble armamentarium” (Knight, 1996) of diagnostic aids. 
It manifests as a plethora of symptoms and reactions that can range widely in their 
severity from mild to deadly. 
 
The term anaphylaxis was coined in 1902 by Portier and Richet, as a descriptive 
term for a particular immunisation protocol they used which exhibited a paradoxical 
effect. 
As a result of their work it was determined that anaphylaxis was an acquired 
sensitivity, manifesting after exposure and re-challenge with an intervening period of 
several weeks. 
Later work, discussed in more detail hereunder, determined the role of antigen 
specific Immunoglobulin E [“IgE”] with the release of preformed mediators such as 
histamine from both mast cells and basophils. 
 
A second type of reaction dubbed “anaphylactoid” has arisen and is characterised by 
a clinically indistinguishable symptomatology, but lacking the IgE antibody mediation, 
and not necessarily requiring previous exposure to the trigger agent. 
In this regard published research seems to implicate IgG1, IgG2 antibodies and their 
recognition by FcɣRIII and FcɣRIV receptors on neutrophils (Lowell, 2011). 
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Common practice however labels both these reactions as “anaphylaxis” despite the 
marked dissimilarities in aetiology. 
Generally, however, it would appear that mast cells and basophils are the primary 
functionaries in the development of an anaphylactic reaction. 
 
The Role of Mast cells per se 
 
The role of mast cells in inflammatory and allergic reactions is well documented.   
Anaphylaxis has been reported as arising from “generalised mast cell degranulation 
caused by immunological reaction” (Osawa et al., 2008). 
 
Mast cells are defined as heavily granulated wandering cells found in connective 
tissue and are abundant beneath epithelial surfaces (Payne & Kam, 2004). In similar 
fashion to eosinophils they stain an intense red with eosin, and are often seen to 
have degranulated in tissue sections. 
Mast cell granules contain a number of proteases, including tryptase together with 
heparin and histamine. Mast cell tryptase [“MCT“] is categorised as a tetrameric 
neutral serine protease comprising four non-covalently bonded subunits.  Two main 
types exist – α and β tryptases. 
 
It has been reported that in severe systemic anaphylaxis serum β-tryptase levels are 
elevated, with levels peaking over a range of fifteen to twenty minutes with a half-life 
of some one and a half to two hours [Payne &Kam 2004], which permits testing of 
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samples obtained over a window period of about one to six hours after the onset of 
the reaction. 
It has been proven that mast cell tryptase levels are relatively stable in the post-
mortem setting, but can exhibit a post-mortem increase, (Horn, Halsey & Zumwalt, 
2004); (Edston & van Hage-Hamsten, 1998); (Edston, Eriksson & van Hage, 
2007)therefore, this permits post-mortem sampling of blood for the determination of 
post-mortem serum tryptase levels, as an indicator [albeit not a determinative 
indicator] of an anaphylactic death.  High levels of tryptase have also been obtained 
three days after a suspected anaphylactic death (Fisher & Baldo, 1998). 
 
Yet, despite its seemingly prominent role as an indicator of anaphylactic reaction, 
high levels of serum tryptase obtained post-mortem may not provide sufficient proof 
of an anaphylactic death, absent other diagnostic criteria. 
This result is borne out by the published research, and at best, although MCT can be 
utilised as an indicator of a possible anaphylactic event, caution needs to be 
exercised as its presence or absence often serves merely as a confounder. This 
phenomenon has been eloquently addressed by Edston et al.( Edston, Eriksson & 
van Hage, 2007)who also found that mast cell tryptase levels can be affected by 
sampling site. They also found that position, resuscitation efforts and the presence or 
absence of conjunctival or facial petechiae have no relevance to MCT levels. 
However femoral blood was the preferred sample, as it is less prone to show false 
results. 
Interestingly, Kounis in a long series of communications has shown that cardiac 
involvement is also prevalent in anaphylactic/anaphylactoid/hypersensitivity 
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reactions, and, not surprisingly, elevated levels of mast cell tryptase in cardiac tissue 
and increased numbers of mast cells have been demonstrated - as have increased 
numbers of basophils and eosinophils. (Kounis et al., 2011a; Kounis et al., 2011b; 
Kounis et al., 2012; Kounis, 2013; Kounis, Soufras & Hahalis, 2014).  This led to his 
sobriquet of anaphylactic cardiac shock [2013 op. cit.] 
Prior to this research, Randall Butts & Halsey (Randall, Butts & Halsey, 1995) 
examined a relatively large [27 and 22 subjects] population of post-mortem tryptase 
levels determined routinely at autopsy in an effort to assess the diagnostic efficacy of 
post-mortem tryptase levels. The sample cases selected by them represented two 
consecutive series of autopsies, where anaphylaxis was not suspected as a cause of 
death. 
Whilst none of the subjects died as a result of anaphylaxis some showed an elevated 
level of mast-cell tryptase but only one subject showed a level that was significantly 
higher [106 µg/L] than the majority of the other observed levels.  It must be noted 
that their selected threshold level was 1ng/ml. They postulated that although an 
elevated post mortem level of mast cell tryptase may be indicative of anaphylaxis, 
utilisation of a threshold value in excess of 10 ng/ml [thus10 µg/L] may provide more 
specificity.  They concluded that an appropriate clinical history coupled with a finding 
of an allergen specific IgE and an elevated tryptase level is strong evidence pointing 
toward an anaphylactic dearth – but it is not conclusive.  It is to be noted that this 
level of mast cell tryptase [10 ng/ml] is markedly lower than the level proposed by 
Mayer et al. [2011, op.cit.] of 45µg/L as indicative of an anaphylactic episode.  Mayer 
P a g e  | 25 
et al. accepted that levels in excess of 11.4 µg/L are within the normal range for 
living subjects. 
 
Returning to the research of Randall et al. they [Randall, Butts & Halsey] thus 
concluded that firstly, a tryptase assay has high level of specificity for anaphylaxis 
provided that the specimen is obtained whilst the patient is still alive, secondly that 
false positives are a rare occurrence. Nonetheless, the caveat sounded above 
should be borne in mind at all times – MCT is as often as not a confounder and 
confuser in the post-mortem diagnosis of anaphylactic death; particularly as it can be 
elevated in traumatic deaths, more especially chest trauma, possibly as a result of 
the traumatic lysis of mast cells followed by degranulation . 
 
This research, although valuable, does not go very far in assisting pathologists in 
determining the cause of death at autopsy where a paucity of diagnostic criteria 
exists. The difficulties encountered in determination of anaphylactic death at post-
mortem are elegantly and succinctly stated by Da Broi & Moreschi (Da Broi & 
Moreschi, 2011):- “coroners and pathologists are well conscious that a post-mortem 
diagnosis of an anaphylaxis hides mores problems and technical difficulties than a 
clinical investigation on a living, atopic patient.” 
 
In 2001, Fineschi et al. (Fineschi et al., 2001) sampled pulmonary tissue in 
anaphylactic, trauma-related and heroin-related deaths.  Samples consisted of 
perihilar tissue and a sample from each lobe of the lung.   Mast cells were counted 
by quantitative morphometry using an area equivalent to 117.7 mm2. The mast cell 
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populations were visualised by immuno-histochemical staining using anti-tryptase 
antibody as a mast cell specific marker.  
As regards the tryptase levels, these were measured in samples of post-mortem 
blood of the selected cases. Their results indicated a significantly raised tryptase 
level in the group diagnosed as anaphylactic deaths, as well as the heroin-related 
death group, compared to the trauma cases [the control group]. 
Their conclusion was that tryptase levels are a good indicator of mast-cell 
degranulation, but they took this postulate no further. 
 
Shen et al., (2009) then published work, in a retrospective study, dealing with a 
review of anaphylactic deaths in Maryland, USA and Shanghai, China, covering 
autopsies from 2004 to 2006.  One of their conclusions [which was consistent with 
other published studies – (Edston& van Hage-Hamsten, 2003); (Randall, Butts & 
Halsey, 1995)] was that elevated mast-cell tryptase, although a good indicator 
thereof, is not an absolute indicator for a diagnosis of anaphylactic death at autopsy. 
 
In 2006 Schwartz, (Schwartz, 2006)theorised that, as tryptase was abundantly and 
selectively produced by mast cells, tryptase levels should provide a more precise 
measure of local or systemic involvement of mast cells than was possible by 
documenting IgE.  Discussing the fact that elevated β-tryptase levels also occurred 
in non-anaphylactic deaths, he stated that, as mast cell activation occurs with 
anaphylactic reactions and hypersensitivity to COX [cyclooxygenase] inhibitors, an 
elevated mast-cell tryptase level found in one case of salicylate overdose could be 
attributable to aspirin sensitivity.  In common with other authors he was thus of the 
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opinion that reliance could not be placed solely on mast-cell tryptase levels in 
determining that the cause of death was due to systemic anaphylaxis, but that regard 
must be had to other diagnostic criteria and aids. 
 
Horn et al. (Horn, Halsey & Zumwalt, 2004) stated that although serum mast cell 
tryptase was a reliable indicator of mast cell activation, combining it with a more 
specific form of assay, such as allergen-specific serum IgE assays might prove to be 
more conclusive.  Citing the work by Randall Butts et al. [1995, supra], elevated mast 
cell tryptase levels were also found in cases of death attributable to cardio-vascular 
disease, as well as in deaths attributable to chest trauma.  They were of the opinion 
that elevated serum tryptase levels in fatal chest injuries could be related to the 
relatively large numbers of mast cells present in lung and gastric tissue.  In respect 
of cardio-vascular deaths they stated that they could not determine whether mast cell 
tryptase levels in both atherosclerotic and chest injury deaths were attributable to 
atherosclerotic plaques [as detailed in the work of Marone et al., 1999] or to 
traumatised mast cells. 
 
Edston& van Hage-Hamsten (Edston& van Hage-Hamsten, 1998) examined β-
tryptase measurements post-mortem and determined that firstly, an elevated level of 
β-tryptase provides a useful adjunct in the confirmation of a suspected acute 
anaphylactic death, secondly that the sampling site for blood used in the 
determination of tryptase levels was an important factor with femoral blood being the 
preferred option.  A second study by the same authors in 2003(Edston & van Hage-
Hamsten, 2003) attempted to confirm their previous work and further to determine if 
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the release of tryptase, after the occurrence of trauma, was acute or delayed.  
Concomitantly with this they attempted to determine the importance of direct trauma 
to, and lysis of, mast cells.  Their results showed that tryptase levels increase shortly 
after trauma and, naturally, that tryptase levels are elevated in circumstances of 
traumatic death.  They thus opined that mast cell degranulation occurs relatively 
early on in response to trauma [this would support and satisfactorily explain our 
observations of elevated mast cell tryptase levels in two of the three case traversed 
above, but which were excluded from the study for various other reasons. The 
causes of death being determined as traumatic head injury and drowning in a bucket 
of urine respectively. The case involving a myocardial infarct was, in fact, included in 
our study.]. 
 
In a departure from the investigations into mast cell tryptase as an indicator in 
anaphylactic, traumatic or cardio-vascular death, Nishio et al. (Nishio et al., 2005) 
examined serum chymase levels in eight cases of anaphylactic death using 104 
cases as controls.  Building on the research already published that mast cell tryptase 
levels were known to be a diagnostic indicator of anaphylaxis they explored the 
relationship between serum tryptase and serum chymase levels.   Their results 
indicated a significant positive correlation of 0.826 [p< 0.05] indicative of the fact that 
serum chymase levels measurements might well be an additional tool in the 
armamentarium of post-mortem diagnostic tools for the determination of anaphylactic 
death. 
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Shanmugam et al. (Shanmugam, Schwartz & Khan, 2006) in a letter to the editor 
documented a case of elevated mature tryptase obtained some twenty-six hours 
after symptom onset. Their patient had been diagnosed with a single episode of 
idiopathic anaphylaxis. 
 
Lastly, Mayer et al (Mayer et al., 2011) reported on the post-mortem levels of 
tryptase histamine and diamine oxidase as indicators supporting a diagnosis of 
anaphylactic death.  Succinctly stated their research showed [in a study involving 
three cases of anaphylactic death compared to 55 controls] that whilst a moderately 
elevated level of mast cell tryptase was common in post-mortem sera, levels in 
excess of 45 µg/l might well be supportive of a diagnosis of fatal anaphylaxis.  
Conversely serum diamine oxidase was singularly unhelpful, whereas a highly 
elevated level of histamine might provide an additional clue pointing toward a fatal 
anaphylaxis. This latter statement, however, may not be of significant value as the 
authors themselves state that [citing the work of Schwartz et al. 1989(Schwartz et 
al., 1989)] histamine’s validity as a marker for living patients is limited owing to its 
short half-life[+/- 15 minutes]coupled with a possibility of non-specific histamine 
release during blood drawing. 
To summarise,  therefore, despite mast cells being regarded as the primary source 
of mediators released on allergen challenge, and although mast cell tryptase would 
seem to be a useful indicator, the very fact that a plethora of triggers can result in 
elevated levels of mast cell tryptase militates against its use as a pathognonomic 
indicator of anaphylaxis.  Some other method that is relatively rapid, cost-effective 
and simple is thus necessary as an aid to routine diagnostic measures in 
determining anaphylaxis at post-mortem.  Here it must be clearly stated that this 
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search for a rapid first line test is purely as a diagnostic aid.  The forensic pathologist 
is still required to have due regard to both anatomical and other histological 
indicators in supporting a diagnosis of anaphylactic death – particularly as mast 
cells, basophils, neutrophils and eosinophils are also implicated as will be seen 
below. 
In seeking this diagnostic aid, regard must be had to the work of Trani et al (Trani et 
al., 2008).The authors in the course of their investigation into four antibiotic related 
cases of anaphylactic death, departed radically from the main stream school of mast 
cell tryptase levels, and focused on the sequelae of mast cell activation, namely 
degranulation and eosinophilia.  Again they departed from the use of conventional 
stains for histological examination of their selected tissue [the spleen] such as H&E 
and Toluidine blue, and also steered away from expensive immunohistochemical 
assays, preferring to explore the use of a commonly available fabric dye, Pagoda 
Red, marketed by DYLON.   
Although this would appear to be a radical and novel departure from the norm, 
previous research had already explored the use of fabric dyes in eosinophil staining 
[(Kiyono et al., 1982); (Yanagihara, Mehregan & Mehregan, 1984); (Battaglia et al., 
1985)]. 
In this study they [Trani et al. 2008] focused primarily on splenic hypereosinophilia as 
a predominant feature for the differential diagnosis of anaphylactic death. This, 
apparently, was in accordance with a number of isolated previous studies.  Their 
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results indicated that tissue sections stained with Pagoda Red exhibited “a diffuse 
perifollicular, cordonal and endosinusal splenic eosinophilia”, together with mast cells 
and degranulated mast cells.  Visualisation of the mast cells, mast cell granules and 
eosinophils was facilitated by the use of Pagoda Red stain, showing up as brilliant 
red on a pale blue counterstained background.  In contrast thereto, non-anaphylactic 
deaths demonstrated only scattered numbers of eosinophils together with mast cells 
exhibiting no degranulation.  In their discussion and conclusion the authors also 
posited a possible eosinophilia in pulmonary and hepatic tissue, as reported by 
Delage & Irey (Delage & Irey, 1972) and by Vance and Stassman [1942], which they 
had also found in two of their cases. 
A fundamental hypothesis of Trani et al.’s research was that in humans the spleen 
acted as a “shock organ”. Some five years later, Marone et al. (Marone et al., 2014) 
postulated the heart as a shock organ. 
 
This research naturally begs the question as to whether the demonstration of a 
diffuse eosinophilia is pathognomonic of anaphylaxis, or whether the combination of 
eosinophilia and degranulated mast cells is the preferred indicator, ever bearing in 
mind that the post-mortem diagnosis of anaphylactic death is fraught with difficulty 
Turning to Marone’s research [cited supra], his researchers, stating that it was trite 
that the human heart is implicated directly or indirectly in anaphylaxis, and citing the 
work of Brockow & Ring [2011]; Criep & Woehler [1971; Hanashiro & Weil [1967]; 
Matucci et al. [2011]; and others [Kounis, op.cit.], went on to show in various articles 
that cardiac mast cells and their mediators play a not insignificant role in both 
systemic and anaphylactic cardiac shock in humans.   
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Co-incidentally in the same year Edston(Edston, 2013) published work where he 
utilised eosinophil, mast cell and basophil counts in the spleen as diagnostic 
adjuncts in determining anaphylactic deaths.  His results demonstrated a significant 
[p< 0.05] increase of eosinophil granulocytes and mast cells in sample tissue versus 
the control tissue.  He also demonstrated that there was no significant difference in 
the mast cell and eosinophil count in pulmonary tissue in anaphylactic deaths when 
compared to tissue from the controls.   This would appear to negate the theory 
proposed by Trani et al. [2008] insofar as eosinophils as a primary indicator of 
anaphylaxis were concerned.  It is however to be noted that Edston restricted his 
examination to splenic and pulmonary tissue only and did not consider hepatic 
tissue. Edston did note, however, that basophils did not feature prominently in his 
examination of tissue.  We therefore discounted the use of basophils as a 
supplementary indicator in our study 
 
Of interest is the fact that he, too, utilised Pagoda Red as a stain according to the 
method proposed by Trani et al. [2008] and also Haematoxylin-Eosin-saffron stain 
according to the method of Edston (Edston 2013).  His observation showed that 
mast cells in pulmonary tissue were located primarily in the bronchial walls and peri-
vascular spaces, exhibiting moreover, an uneven distribution.  Very few eosinophils 
were observed.  In the spleen, however, the number of mast cells and eosinophils 
varied widely from case to case, being located mainly in the red pulp.  Eosinophil 
counts showed a significant difference compared to control numbers with a mean of 
26.16 +/- 17.8/SD/ per 40x field in the samples versus a mean of 7.0 +/- 10.5 in the 
controls. 
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A further factor of interest was his finding that opiate associated deaths 
demonstrated no significant difference in eosinophil counts.  Our records however 
show one instance of an opiate-related death [following the use of self-administered 
continuous ambulatory pain control protocol utilizing intravenous Morphine] where 
the levels of mast-cell tryptase were not significantly elevated [33.2 µg/L], a finding 
somewhat at odds with Fineschi et al.’s research [op.cit.]. This case, unfortunately, 
did not satisfy the criteria for inclusion in our study; nevertheless, we deemed it 
prudent to examine the spleen and heart tissue. 
 
As an aside to this seemingly anomalous observation, regard must be had to the 
published work of Maurer et al. (Maurer et al., 2014), where it was found that the 
symptoms of heroin intoxication combined with asphyxia and/or cardiac involvement 
resemble anaphylaxis.  Speculatively they determined that such drug–related deaths 
may be attributable to an allergic reaction. 
 
 Stepping back two years to 2012, we find that Stone & Brown (Stone & Brown, 
2012)] state that direct activation of mast cells by opiates [specifically mentioned are 
morphine and codeine] can occur.  That being the case, these two published articles 
offer an elegant explanation of the death mentioned above, but a closer histological 
examination of our case mentioned above would thus seem to be in order. 
 
Returning to the research of Edston [op cit. 2013], we find that one of his principal 
findings was that Pagoda Red did not differentiate between eosinophils and mast 
cells, secondly that it was not as sensitive as immunohistochemical staining with 
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monoclonal antibodies- those utilised being tryptase antibody [supplier Dako] and 
chymase antibody [supplier Nordic Biosite], for the visualisation of connective tissue 
mast cells;  major basic protein “MBP “ for eosinophil visualisation and pro MBP1 
[both supplied by Nordic Biosite] for basophil visualisation. 
 
An excursus on Anaphylaxis 
 
 
Anaphylaxis is a severe systemic allergic reaction that can involve multiple systems 
of the body. It is often unpredictable, can have a rapid onset and, if serious, can 
have life-threatening and often fatal consequences. 
 
If the reaction is attributable to, or precipitated by, an antigen antibody response, it is 
considered anaphylaxis, if however, it is caused by a non-antibody trigger, it is 
considered to be anaphylactoid in nature. 
 
Notwithstanding this subtle difference, clinically, both responses present with the 
same symptoms and require the same management and treatment, and obviously 
both reactions are potentially fatal.  
 
It is common knowledge, and has been for decades, that histamine is a primary 
mediator of anaphylaxis, further that challenge by means of a histamine infusion can 
reproduce the signs and symptoms of anaphylactic reaction. 
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 Histamine, as is now well-known, triggers a cascade of inflammatory mediators and 
modulates its own release. H1-antihistamines are used as adjunctive treatment for 
acute anaphylaxis and anaphylactoid reactions, in which many mediators of 
inflammation are involved.  
 
Research soon led to anaphylaxis being understood as a hyper-acute allergic 
syndrome, which is systemic in nature. Since then research has sought to establish 
which mechanisms, unique or not, were able to adequately explain the paradoxical 
response of the human immune system generating a potentially fatal disease state 
when challenged with, and reacting to, seemingly innocuous environmental 
substances such as animal hair [cats seem to be the favoured species!],certain 
foodstuffs [for example nuts], and house dust. 
At this stage, a brief historical examination of the disease state is apposite. 
In 1910, histamine was first found to reproduce anaphylactic symptoms (Dale & 
Laidlaw, 1910). Later, in the 1950s, histamine was found in cells present as a minor 
population in tissues (RILEY, 1953) and, in the 1960s, these cells, now known as 
mast cells, were shown to degranulate and release histamine when challenged with 
an antibody and antigen (Prouvost-Danon, Javierre & Lima, 1966) 
 
1966 saw the discovery of a unique “Erythema–wheal reaction-inducing 
Immunoglobulin” [which led to the mnemonic IgE], present in minute amounts in 
plasma (Ishizaka, Ishizaka & Hornbrook, 1966).  Shortly thereafter it was found to be 
secreted in large amounts by a rare plasmacytoma (Johansson & Bennich, 1967).  
Then in 1969 it was described, and allergic reactions were attributed to it. (Bennich 
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et al., 1969).This substance [IgE] was found to be cytotropic, (Evans & Thomson, 
1972). In the same decade a receptor with a uniquely high affinity for IgE was 
described by Kulczycki et al. as occurring on mast cells and basophils (Kulczycki, 
Isersky & Metzger, 1974).  This was then described and labelled FcεRI, by Blank et 
al., (Blank et al., 1989) and cloned by them. The 3D structure of this substance was 
published in1998 by Garman et al. (Garman, Kinect & Jardetzky, 1998). The 
allergen-IgE-FcεRI-mast cell-histamine-clinical-symptoms sequence subsequently 
constituted the paradigm of allergic reactions. 
Antibodies other than IgE have also been shown to contribute to allergic responses, 
and similarly evidence has accumulated that mast cells, basophils, eosinophils, 
neutrophils, monocytes, T-cells and NK cells are implicated in allergic reactions. 
(Jonsson & Daeron, 2012). 
In particular, Jonsson et al [(Jonsson et al., 2011), cited by Lowell [supra], implicate 
IgG1, IgG2 antibodies and their recognition by FcɣRIII and FcɣRIV receptors on 
neutrophils.  Lowell [op cit.] presents an elegant simplified diagrammatic 
representation of the pattern of mediator release from mast cells via the commonly 
accepted mast cell – FcξRI pattern, as well as the sequence for the FcɣRIII/ IgGI –
Basophil Platelet Activating Factor pathway and the FcɣRIV/IgG2-Neutrophil Platelet 
Activating Factor pathway. 
The involvement of eosinophils in the anaphylactic process, coupled with published 
research that posited that the human spleen as a shock organ demonstrated a 
diffuse eosinophilia in cases of anaphylactic death, gave rise to the interest in this 
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particular study in rendering eosinophils more readily visible, particularly when the 
pathologist is faced with determining cause of death by autopsy. 
 
The use of eosinophils as a diagnostic adjunct in preference, alternatively in addition, 
to the use of mast cell tryptase would appear to be a departure from mainstream 
thought on the applicable diagnostic criteria. 
 
  The problems arising in diagnosis in the living are multiplied exponentially in the 
deceased; hence any adjunct that would facilitate the rapid, reliable differential 
diagnosis of anaphylaxis at autopsy would obviously be most welcome. 
 
The Role of Eosinophils 
 
 
The role of IgE in mediating eosinophil activation has been somewhat controversial.  
It has been found that eosinophils can potentially express three types of IgE 
receptors: a low-affinity IgE receptor, a lectin-type IgE-binding molecule, and a high-
affinity IgE receptor (Truong et al., 1993). Claims have been made that the latter, 
high affinity IgE receptor, FcεRI, is present on eosinophils from patients with 
eosinophilia and that eosinophilic degranulation [and parasite cytotoxicity], is 
mediated through this receptor (Gounni et al., 1994). 
 
Conversely, it has been found that the number of high-affinity receptors expressed 
on the surfaces of eosinophils from patients with allergic diseases or airway 
eosinophilia was minimal or undetectable (Seminario et al., 1999). 
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Then, yet again, the research of Lowell and Jönsson [2011, supra] indicates the 
involvement of the FcɣRIII and FcɣRIV receptors on both neutrophils and basophils.  
Clearly more research in this field is needed, however, this study is concentrating on 
the role and accumulation of eosinophils in the spleen as an indicator of anaphylactic 
death, when examined post-mortem and research into the former is thus beyond the 
scope of this study. 
 
Complicating the role of eosinophils in anaphylaxis is the fact that, although 
eosinophils comprise part, and are formed elements, of the peripheral circulation, 
they are primarily tissue-dwelling cells, and in the healthy individual, most 
eosinophils are found in the gut (but not in the oesophagus), mammary gland, 
uterus, thymus and bone marrow.  It has also been found that the predominant 
population of eosinophils is found in the gastro-intestinal tract (Mishra et al., 1999). 
 
The baseline state of eosinophils present in the gastrointestinal tract is independent 
of adaptive immunity and enteric flora; their levels being regulated by the constitutive 
expression of eotaxin-1 and eosinophil chemokine receptor, CCR3 (Pope et al., 
2005; Humbles et al., 2002).  Eosinophils also settle in, or more specifically home 
into, the thymus, mammary gland, and uterus (Gouon-Evans, Rothenberg & Pollard, 
2000). 
 
 Thus the article by Trani et al [ 2008] postulating the spleen as a shock organ in 
humans, and that it will exhibit a marked eosinophilia in anaphylaxis is novel, and if 
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confirmed by this research will materially assist local pathologists in determining 
anaphylaxis at autopsy. 
 
Confounding the issue though, is the published research of Maurone et al. [2013] 
and the report of Matucci et al. [2010], when read with the research of Kounis et al. 
[2013, 2014].  This latter research traversed the postulate that owing to the presence 
of mast cells in cardiac tissue [intimal, interstitial, perivascular and adventitial mast 
cells], an IgE or non IgE mediated event will trigger the massive degranulation of 
these mast cells with predictable results.  Kounis [2013] opines that although cases 
of sudden death are often attributed to cardiac involvement, unrecognised 
anaphylaxis may accompany up to 13% of such deaths.  Although he goes further to 
state that an increased presence of mast cells visualised with Toluidine blue stain 
was demonstrated in the coronary arteries, particularly the left anterior descending 
artery,  he ends his discussion with the statement that histologic examination of the  
heart particularly the coronary arteries may well demonstrate mast cells  and 
eosinophils.  This latter observation is obviously important for our study 
 
Historical overview of Eosinophils. 
 
The eosinophil granulocyte was awarded this appellation by Paul Ehrlich in 1879 
owing to the intense staining of its granules with the acidic dye eosin (Gleich & 
Adolphson, 1986) – staining the cell an intense red thereby making it  readily visible 
on examination. 
 
 Since then the eosinophil has been the subject of extensive investigation, and as a 
result thereof its prevalence in widely disparate conditions such as parasitic 
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infections and hypersensitivity diseases (including anaphylaxis) has become better 
understood.  
 
In Th2-type immune responses, eosinophils are recruited into sites of inflammation 
where they then produce an array of cytokines and lipid mediators, and also release 
toxic granule proteins. 
From this it can be seen that the Eosinophil plays a significant role in a variety of 
settings in the human body, and therefore in forensic autopsy setting, fast reliable 
methods of visualising eosinophils in various tissues should markedly speed up the 
differential diagnosis of an anaphylactic/anaphylactoid death. 
It is trite that the complicating factor in forensic autopsy cases is the exact 
determination of the cause of death.  Was this death anaphylactic, anaphylactoid or 
attributable to some other disease process, or was it indeed an unnatural death? A 
question that should always be posed by the forensic pathologist. 
Diagnosis of anaphylactic type reactions [a generic use of the word to cover both 
anaphylactic and anaphylactoid reactions] is, as a rule, difficult.  In the Forensic 
Pathology setting at autopsy this difficulty is markedly increased. 
Typically in the Forensic pathology setting, a detailed history may well be 
unavailable, reference levels of ante-mortem biochemical markers may not have 
been taken or may be unavailable, alternatively no witnesses to the fatal event may 
be present, and clinical symptoms may be unknown.  Testimony to the comment of 
Da Broi & Moreschi [supra, op. cit.] 
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Criteria for the diagnosis of the disease state have been elegantly formulated as 
follows [(Khan et al., 2013) citing (Sampson et al., 2006)]: 
“Anaphylaxis is highly likely when any one of the following three criteria is fulfilled: 
 
Acute onset of an illness (minutes to several hours) with involvement of the skin, 
mucosal tissue, or both (e.g. generalized hives, pruritus or flushing, swollen lips–
tongue–uvula). AND at least one of the following: 
(a) Respiratory distress (e.g. dyspnoea, wheeze-bronchospasm, stridor, reduced 
Peak Expiratory Flow (PEF), hypoxaemia) 
(b) Reduced blood pressure [“BP”] or associated symptoms of end-organ 
dysfunction (e.g. hypotonia, syncope, incontinence). 
 
Two or more of the following that occur rapidly after exposure to a possible allergen 
for that particular patient (minutes to several hours): 
(a) Skin–mucosal tissue Involvement (e.g. generalized hives, itch-flush, swollen 
lips–tongue–uvula). 
 
(b) Respiratory distress as outlined above 
 
(c) Reduced BP or associated symptoms (e.g. hypotonia [collapse], syncope, 
incontinence). 
 
(d) Persistent gastrointestinal symptoms (e.g. cramps, abdominal pain, vomiting). 
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 Reduced BP after exposure to a known allergen for that particular patient (minutes 
to several hours): 
 
(a) For Infants and children: low systolic BP (age specific) or >30% 
decrease in systolic BP. 
(b) For adults: systolic BP of <90mmHg or >30% decrease from that 
person’s baseline.” 
 
As can readily be seen these diagnostic criteria [ conveniently summarised as 
History; Known exposure to a trigger; and Clinical signs and Symptoms],  require 
input from the patient or a detailed history both of which are, more often than not, 
sorely lacking at the stage of a forensic autopsy. 
 
A further complicating factor is that a significant amount of research has 
demonstrated that mast cell tryptase [“MCT”] is a significant biomarker that can 
support a diagnosis of anaphylactic death, but not necessarily so, and would seem 
not to be pathognonomic. Elevated MCT levels are thus not diagnostic on their own 
as they are seen in both general and forensic medicine 
[The various published explanations for these seeming anomalies observed with 
mast cell tryptase have been traversed above under the heading of mast cells.] 
It is thus hypothesised that MCT levels, although sometimes providing a useful 
guideline to the cause of death, can be a significant confounder and confuser in the 
post-mortem determination of the cause of death. 
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Furthermore, in the forensic autopsy setting, baseline levels taken ante-mortem, are 
more often than not unavailable, hence reliance [possibly unwarranted] at autopsy, is 
placed on a generally accepted “normal level “of MCT as the baseline value 
[postulated variously as 10ng/ml or 45μg/l supra] might well be misplaced, when in 
fact the normal value for a particular patient may well be markedly above this 
artificially determined “normal level”. 
Intriguingly recent studies have shown that although an elevated post-mortem MCT 
level can be indicative of an anaphylaxis related death, so too can an elevated level 
of MCT be found in cardio-vascular disease related deaths, in trauma and in drug 
related deaths as stated above. 
On the positive side, MCT has been shown to be relatively stable and with a long 
half-life, making it suitable as a post-mortem marker, in contrast to its shorter lived 
analogue histamine (Edston, 2013). 
Evaluation& Concluding remarks 
Trani et al. (2008) had already stated in their research that both eosinophils and 
mast cells showed up as brilliant red when stained with Pagoda Red, and had 
accumulated in the spleen, in cases of anaphylactic death. This was confirmed by 
Edston (Edston, 2013), in a study of 43 cases. 
Kounis and Matucci [supra] subsequently theorised that cardiac tissue is involved in 
anaphylaxis and demonstrates increased levels of mast cells and degranulation, 
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ergo, eosinophils should also be found in cardiac tissue as a pointer to “Kounis 
syndrome” or similar anaphylactic death. 
 
Returning to Trani et al.’s research, it would thus appear that a correct interpretation 
of their work is that the presence of large numbers of both eosinophils and 
degranulated mast cells in splenic tissue would be indicative of a possible 
anaphylaxis.  At no stage did they claim that their method differentiated between 
eosinophils and mast cells.  
 
 As regards immunohistochemical staining, this is generally accepted as the “gold 
standard” for staining, yet its cost remains prohibitive in certain resource challenged 
environments, such as ours. 
 
Relating these various published articles to the situation found in Cape Town, it can 
be stated that: 
Firstly, the problems experienced world–wide in the post mortem diagnosis of 
anaphylaxis are also found locally.   
Secondly, although it is recognised that immuno-histochemical staining is the gold 
standard for diagnosis as set out above; in the local situation costs of obtaining such 
slides are prohibitive [ supra] and in consequence thereof unsuitable for routine day 
to day use.  The budget for forensic pathology services in the local setting is severely 
constrained, and is combined with a heavy workload of cases. Simply put the local 
pathologists do not have the twin luxuries of time and funds to obtain routine 
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immuno-histochemical staining of tissue to aid their possible diagnosis of 
anaphylactic death.   By way of example, the South African costs for mast cell 
specific immuno-histochemical staining of tissue are some ZAR900.00 per slide, 
[written quote, National Health Laboratory Services, 26 August 2014], whereas, if 
proved to be efficacious, the use of a local dye reduces the cost to approximately 
R75.00per slide. [Histology Section of Division of Forensic Medicine and Toxicology, 
oral communication, 2014]. Its use as a diagnostic criterion would thus be of 
immense value. 
 
Thus, if this research confirms the postulates of Trani et al. [2008], and if the local 
dye shows no statistically significant variation of eosinophil counts when compared 
with Pagoda Red dye, then local pathologists can utilise this low cost local dye 
secure in the knowledge that it replicates the published research using Pagoda Red 
in a statistically valid fashion.   
 
It was determined that the dye Pagoda Red was not readily available locally or in 
South Africa, hence a local dye was selected.  The local dye selected is 
manufactured by Lady Dye, apparently a South African company but very little detail 
is available.  The dye selected is marketed as Lady Dye “Magenta”. 
 
Nonetheless should the local dye prove inefficacious, the use of Pagoda Red dye, 
despite difficulties in obtaining it locally, may well prove to be a powerful tool in the 
visualisation of eosinophils in splenic hypereosinophilia. 
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SECTION C: PUBLICATION READY ARTICLE (Incorporating method, results & 
discussion. For submission to Journal of Forensic Sciences) 
 
TITLE:  A follow-up study using fabric dye to visualise Eosinophils as an aid to 
diagnosing Anaphylactic Death in Forensic Autopsies. 
 
Authors: P.J. Burgers; University of Cape Town Dept. of Forensic Pathology; Dr. L. 
Liebenberg, University of Cape Town Dept. of Forensic Pathology; Ms Y Davies, 
University of Cape Town Dept. of Forensic Pathology; Ms Y Perrins, University of 




A retrospective study of anaphylactic deaths was undertaken, with a view to 
determining if splenic eosinophilia was present, as well as if it was easily visualised 
using a cheap fabric dye as previously published. 
Two common fabric dyes; one local, cheap and readily available, MagentaTM and 
Pagoda Red TM manufactured by DYLON TM, imported as it was not locally available; 
as stains to visualise eosinophils were used.  Haematoxylin/Eosin [H&E] was used 
as a control. 
Simultaneously the study sought to determine if post-mortem mast cell tryptase 
levels were a reliable diagnostic indicator of anaphylactic death. 
 
It was found that there was no significant difference in eosinophil counts between 
anaphylactic cases and controls at the p < 0.05 level. 
 
No significant difference in eosinophil counts between the various stains used was 
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demonstrated. Pagoda Red rendered eosinophils more easily visible, resulting in a 
reduced amount of time spent in counting.  
 
Lastly there was no significant difference [p<0.05] between the mast cell tryptase 
levels of anaphylactic deaths and control samples. 
 




Anaphylaxis is an intriguing entity. It may manifest in a protean number of situations: 
idiosyncratic, manifesting after previous exposure to an allergen, as a de novo 
occurrence in procedure-related events, and also as undocumented [in the sense 
that no hospital records, or detailed history is available], unwitnessed deaths.  
Clinical diagnosis in survivors requires some effort in documenting the cascade of 
physiological events, particularly if the causative agent must be identified for future 
desensitisation or avoidance of a repeat challenge.  
  Diagnosis of anaphylaxis as the cause of death at autopsy is even more 
complicated as the normal diagnostic armamentarium is significantly impoverished, 
the death commonly being undocumented, and unwitnessed. Furthermore the many 
ante-mortem clinical baselines and usual indicators of anaphylaxis change or may 
disappear. Diagnosis thus relies mainly on the exclusion of other factors coupled, 
where possible, with patient history, histological examination and with appropriate 
biochemical testing of appropriate tissue samples. These diagnoses are thus 
notoriously difficult [1-4], and it is commonly known that these diagnoses cannot rely 
on any one single factor, but on a combination of factors. 
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The role of mast cells in inflammatory reactions and anaphylactic shock has been 
well established for a considerable period of time [5-9]. 
 
It is also well understood that histamine, being the main mediator of anaphylaxis, 
presents special difficulties for post-mortem analysis/determination owing to its 
manifestly short half-life [10].  The same however is not true for mast cell tryptase, it 
having been shown to be relatively stable in post-mortem blood [11,12] This naturally 
provides a useful post-mortem indication of mast cell activation, possibly indicative of 
an anaphylactic, [or anaphylactoid] death.  
Frustratingly though, it has been shown that elevated levels of mast cell tryptase at 
post-mortem have occurred where the cause of death has been shown as being 
unrelated to anaphylaxis [12].  It is thus unsafe to rely solely on mast cell tryptase as 
the only indicator of anaphylactic death.  The use of IgE levels to assist in the 
determination of anaphylactic death does not seem to be widely used. 
 
Eosinophilia and oedema in the upper airways has been shown to be a common, but 
not omnipresent, finding in anaphylactic deaths [2].  It has been shown that there 
would appear to be no demonstrable eosinophilia in pulmonary tissue in anaphylactic 
deaths, but a confirmed splenic eosinophilia [3, 6, 7, 13], it was also shown that a 
high level of mast cell tryptase was linked to an increased number of eosinophils and 
mast cells in splenic tissue. [6] 
This short study attempts to replicate the results obtained by Trani et al. [7], but 
using a locally available fabric dye, as DYLON TM  Pagoda Red is locally unavailable, 
and to determine if splenic eosinophilia could be demonstrated in all anaphylactic 
death cases considered.  A superficial examination of a possible correlation between 
mast cell tryptase levels anaphylaxis, and splenic eosinophilia was also performed. 
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Methods 
Ethics approval for the study having been granted by the Health Sciences Faculty 
of the University of Cape Town ethics committee under the reference HREC/REF 
088/2015, a retrospective study of forensic autopsy files at the Salt River Forensic 
Pathology Laboratory, Division of Forensic Medicine at the University of Cape Town, 
in Cape Town was conducted, covering the period 2002 to 2015. Cases where 
anaphylaxis was diagnosed as the cause of death were identified. A cohort of non-
anaphylactic death cases was also identified. 
Selection criteria for both test and control cases were: similar age and gender [as far 
as was practically possible; availability of spleen tissue and mast cell tryptase [MCT] 
levels. Sample and control cases were scrutinised by a senior forensic pathologist. 
The selection took place in accordance with the following 5 step protocol: 
1 Cases where a mast cell tryptase level was available were identified from a 
spreadsheet of forensic autopsy cases with mast cell tryptase levels recorded by 
the UCT Lung Institute; 
2 Thereafter, the hard copy documents [archive records] of all identified cases were 
retrieved for scrutiny by the researchers; 
3 Documentation was carefully examined to determine if appropriate histological 
specimens had been kept. 
4 Histological samples were then examined to ensure that a spleen sample was in 
fact available. 
5 Each case was exhaustively reviewed by a Senior Forensic Pathologist to 
determine if the diagnosis was one of anaphylaxis or one positively excluding 
anaphylaxis.  These identified cases then formed the basis of our study. 
  A variety of clear-cut non-anaphylactic causes of death were noted in the control 
cases, including drowning, air embolism, cardiac disease and gunshot wounds and 
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complex disease profiles.  As mentioned before the availability of mast cell tryptase 
levels and a spleen section were pre-requisites. On this basis it was possible to 
select nine cases where anaphylaxis was determined to be the cause of death, ten 
cases where cause of death was not anaphylaxis, plus four other cases included as 
controls owing to complex pathology, but where anaphylaxis as the cause of death 
had been excluded. One of the nine cases had two different paraffin embedded  
sections of spleen [listed as Block 6 and Block 7 respectively, samples D & K] as a 
further internal control, giving a total of ten sample slides, and a total of  fourteen 
control slides. The master data table of the cases selected for both samples and 
controls is reflected in table 1. 
 
Blood for MCT levels was femoral blood in accordance with standard operating 
protocols in the Salt River Forensic Pathology Laboratory. Post-mortem intervals 
varied between less than five hours to seven days after death. These survival times 
are also detailed in table 1.  Table 2 is a key to the study samples, detailing the 
alphabetic character identifying each sample, the pathology services case number, 
the diagnosis, cause of death and the mast cell tryptase level. 
 
Tissue samples of spleen were processed in our histology laboratory and each 
sample stained with, variously:  H&E, Pagoda Red (according to the method of Trani 
et al.) [7] and a locally manufactured fabric dye called “Magenta”. Allergic nasal 
polyps, rich in eosinophils and mast cells were used as an internal control.  
 
In the case of the sections stained with Magenta, the method we developed was as 
follows: 
Sections of paraffin wax embedded splenic tissue of 5, 3, and 1.5 micron thickness 
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were stained to determine the optimum tissue section thickness.  It was found that 
the standard 1.5 micron section gave the best results as far as dye uptake, colour 
and contrast were concerned. 
 
Thereafter the pH of the Pagoda Red solution was measured and the pH of the 
Magenta solution adjusted to match [pH 4.15]. 
 
Sections were then stained in the aqueous Magenta solution [1%] for a period of one 
hour at 550 C, washed in water for 1 minute, counter stained with Harris 
Haematoxylin solution for one minute, again washed for one minute in water, 
followed by Scott’s solution for one minute.  A further wash in water for a one minute 
period was performed, whereafter the slides were washed in successive alcohol 
baths and clarified with Xylol as per the H&E staining method. 
 
No immunohistochemical staining was performed as in our case costs are prohibitive 
and only one laboratory in the country has the capability to perform this type of 
processing. The laboratory concerned also cannot perform the specific test 
mentioned in the literature, but can perform a generic type of mast cell 
immunohistochemical staining [CD 117, cost ZAR 900.00 per slide]] 
 
At this stage the triplicate sets of spleen slides [comprising H&E, Magenta & Pagoda 
Red stains], were randomly coded alphabetically by the histotechnologist, Ms Y. 
Davies, to anonymise the case numbers.  This was done in order to blind the 
analysts as to whether a specific slide/section originated from a sample case, or 
control case. 
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Eosinophil counts were performed in ten randomly selected x 40 fields that had been 
digitally captured and recorded with an Olympus BX43F photo microscope. 
 
One analyst preferred to count the cells directly using a standard binocular 
microscope [LL], the other analyst preferring to use the photo-micrographs. [PB] 
 
The two analysts [Dr. Liebenberg “LL”, forensic pathologist; P Burgers “PB”, student]  
[PB] were then given the slides and eosinophils visible were counted as set out 
below. 
 
Once the counting of eosinophils had been completed the slides were de-
anonymised to reveal the alpha-numerical details of each set, and these data were 
then used to draw up the tables of results. 
 
The data was statistically analysed using Wilcoxon rank-sum method. Means and 
standard deviations were routinely calculated.  Significant differences were defined 







Median cell counts per analyst were statistically evaluated using the Wilcoxon rank 
sum test. The total cell counts [10 random fields] per slide per stain are shown in 
table 3. 
 
P a g e  | 53 
Statistically significant discrepancies in inter-observer cell counts were found as 
follows: 
The experienced analyst, “LL”, using a microscope field for counting, demonstrated a 
significant [p< 0.05] difference in cell counts as set out in table 4. 
 
The inexperienced analyst, “PB”, counting from the photomicrographs, demonstrated 
a greater consistency in cell counts, but demonstrated significant differences in cell 
counts as set out in table 5 
 
 
Bearing in mind that there were a total of twenty two different cases, it is apparent 
that the experienced analyst [in excess of twenty years’ experience]  demonstrated 
significant differences in a far greater number of cases than the inexperienced [one 
year’s experience] analyst.  The experienced analyst showed a bias in favour of cell 
counts with H&E, followed by Pagoda Red, and trailed by the Magenta stain.     
 
The Magenta stain proved disappointing in its application, it being difficult to identify 
eosinophils in congested splenic tissue.  In a few of the study samples it was 
reported that the use of Magenta, despite it not being as effective as Pagoda Red, 
certainly rendered the eosinophils more readily visible than the H&E stained 
samples.  Generally these were samples where congestion was absent 
 
Thereafter, and once the various diagnoses of the cases were revealed, the 
anaphylaxis cases were compared to the control cases and secondary control cases 
by means of a Wilcoxon rank-sum test, using the cell counts obtained with the three 
different stains. 
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As before the results were separated into those obtained by the experienced analyst 
and those obtained by the inexperienced analyst and grouped appropriately. 
Without exception we demonstrated that there were no significant differences 
between test, control and secondary control cases’ eosinophil counts, across all 
three stains. 
 
Lastly, we determined the Spearman correlation co-efficients between the eosinophil 
counts and mast cell tryptase levels, for the sample cases [anaphylactic deaths] and 
the control cases, per analyst.  
 
We determined that there was no statistically significant correlation [rho = -0.13374 
for the H&E sample cases; -0.13982 for the Pagoda Red sample cases; 0.139 and 
0.182 for the control cases, respectively] between mast cell tryptase levels and a 
diagnosis of anaphylactic death. 
 
In all cases it was found that the number of eosinophils present was significantly 
lower than previously reported [6, 7].  The summary of means, medians etc. is 
reflected in tables 6 and 7.   
 
Our results indicate that whilst mast cells may not be clearly differentiated from 
eosinophils in a routine stain [H&E], the use of Pagoda Red particularly, and to a 
lesser extent our local dye Magenta, renders mast cells far more easily 
distinguishable from eosinophils than is possible with a routinely stained slide 
[H&E].thereby rendering both mast cells and eosinophils highly visible and capable 
of being rapidly counted.  With Pagoda Red we noted that the granules from 
degranulated mast cells appeared as brick red clumps similar in appearance to 
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caviar, and thus readily identifiable and distinguishable from eosinophils. 
Elevated Mast Cell Tryptase level in Anaphylaxis. 
 
In two confirmed cases of anaphylaxis, ante-mortem sera could be obtained as 
base-line values.  In these two hospital-setting deaths, the time frames of 
anaphylaxis as well as the causative agents were documented.  Mast cell tryptase 
levels were 5.7 µg/l ante-mortem, and 19.5 µg/l post-mortem [sample N, table 1]. 
The ante-mortem baseline value in the second case was 10.4 µg/l, post arrest, 18.1 
µg/l and at autopsy 39.5 µg/l [sample U, table1].  In both cases the mast cell tryptase 
level did not exceed the 45 µg/l level [12].    
 
On an individual basis our findings did not seem to support the theory that an 
elevated mast cell tryptase level went hand in hand with anaphylaxis. When 
combined the mean values of MCT in the anaphylactic samples were 278.85µg/l with 
an SD of 151.21 µg/l, with a range from 16.4 to 1530 µg/l, whereas with the control 
group the mean value was shown to be 38.758 µg/l with an SD of 18.35 µg/l, and a 
range from 3.68 to 200 µg/l.  Our combined results would seem to support the 
previous research [6] that elevated MCT levels are frequently, but not consistently, 
found with anaphylactic deaths. Because of the extreme variability of the ranges we 
deem it prudent to continue this research in an effort to expand diagnostic 






A retrospective study has inherent limitations.  Autopsies cannot be performed again; 
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tissue cannot be resampled, the particular pathologist who performed the autopsy 
may no longer be available, and the rationale for the obtaining of mast cell tryptase 
levels, in itself a specialised test, may not be reflected in the documentation.  
Hospital records may not be available and owing to the effluxion of time may not be 
traceable.   
Anaphylactic deaths are notoriously difficult to diagnose, and generally rely on the 
exclusion of other causes of death coupled with exhaustive testing and histological 
examination.  Numbers of anaphylactic deaths in the records are generally low. 
Splenic eosinophilia 
Having examined the results obtained by both analysts, we would cautiously 
conclude as follows. 
That in the subjective opinion of the experienced analyst Pagoda Red rendered the 
eosinophils more easily visible than traditional H&E stain, thereby markedly reducing 
time spent in counting [although this was not measured or recorded]. 
In the hands of the inexperienced analyst, the variations were far less numerous, but 
his opinion mirrored the opinion of the experienced analyst as regards visibility of 
eosinophils.  That is:  H&E followed by Pagoda Red and again trailed by Magenta.  
This analyst echoed the sentiments of the experienced analyst that the Pagoda Red 
stain rendered eosinophils far more easily visible. We would suggest that, based on 
the number of significant differences exhibited in the sample counts in the hands of 
the inexperienced analyst, an inexperienced analyst would benefit more by the use 
of Pagoda Red or H&E stain, rather than the local Magenta stain we tested; secondly 
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that in the case of experienced analysts the stains of choice would be H&E or 
Pagoda Red.  It is noted that the demonstrated efficiency of Pagoda red mirrors the 
findings of Trani et al. and Edston [6, 7]. 
 
 
 We could not confirm, statistically, a splenic eosinophilia in anaphylactic deaths as 
reported [6, 7].  Only one of the nine sample cases, sample V in table 1, [comprising 
ten mounted sections of tissue] demonstrated an eosinophil count of greater than ten 
in each field.   
At this point it must be mentioned that shortly before the completion of the study, we 
evaluated the following cases: 
 
Case 1: This particular case was unique as it proved to be a case of nematode 
infestation, possibly Anisakis simplex, in a fish factory worker who was otherwise 
healthy. This case was reflected as sample V in the study. The subject had returned 
home from work with no complaints, went outside, and was found dead twenty 
minutes later. Toxicology screen demonstrated no alcohol in the blood, and 
paracetamol on the urine only.  Apart from a massive splenic eosinophilia, 
eosinophilic granulomata with Charcot Leyden crystals around remnants of 
nematode cuticle were visible in the liver. Total IgE was 124, MCT was 28 µg/L, and 
Anisakis specific IgE was 0.12. [levels of<0.1kU/l are regarded as below the reliable 
detection limit; 0.1-0.35 kU/l very low and >100kU/l extremely high. A low specific 
IgE is apparently often found in allergy cases.  A positive test is regarded as 
conclusive, a negative test is inconclusive. [Personal communication, Ms. B 
Fenimore, Medical Technologist, Allergology, Diagnostic & Clinical Research Unit, 
UCT Lung Institute, 6 June 2012] 
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Case 2: was that of a 24 year old female who died under suspicious circumstances, 
whilst engaged in sexual activity. At autopsy she was found to have swollen pale 
tracheal mucosa, and puffy lungs. She also exhibited a congested spleen, with a 
marked eosinophilia in the stomach mucosa, a normal mast cell tryptase level, but a 
markedly elevated IgE level [Total IgE 436; MCT 20.4µg/L; Latex specific IgE 
0.06kU/l]. Toxicology screen demonstrated no drugs of abuse or alcohol in the blood. 
This case proved to be an anaphylactic death most likely attributable to latex allergy 
from the condom that was used.  A sample of spleen tissue was stained as per the 
protocols above, was disappointing as it was too congested to permit cell counting. 
 
Eosinophilia and Mast Cell Tryptase 
 
Our results could not confirm a correlation between MCT levels and splenic 
eosinophilia. Spearman coefficients demonstrated no significant correlations. 
 
Differentiation of Mast Cells and Eosinophils. 
 
 
The result that eosinophils and mast cells are rapidly distinguishable when stained 
with Pagoda Red, and to a lesser extent Magenta is significant in that analysts 
performing cell counts can quickly distinguish between the two and cell counting is 
markedly facilitated. With Pagoda Red we noted that the granules from degranulated 
mast cells appeared as brick red clumps similar in appearance to caviar, and thus 
readily identifiable and distinguishable from eosinophils.  A considerable amount of 
time saved in cell counting is achieved. 
 
P a g e  | 59 
Conclusions 
 
Based on our research we concluded that there is most definitely a place for the use 
of rapid dye staining techniques such Pagoda Red [6, 7, 13] and to a lesser extent, 
our local Magenta dye.  The significance of this in a resource-challenged 
environment where routine immunohistochemical staining cannot be achieved 
should not be under-estimated.   
 
Our results could not confirm the findings of Trani et al. and Edston [6, 7], that a 
splenic hypereosinophilia was present in anaphylactic deaths. Nonetheless we 
determined that Pagoda Red staining of tissue samples has a number of other 
possible applications. 
 
Apart from anaphylaxis, a number of disease processes elicit eosinophilia.   
 
Apart from Forensic Pathology, we suggest a number of applications of Pagoda Red 
in the fields of surgery and medicine, which may be of particular value and 
applicability in a resource challenged environment: 
- Bronchial aspirates with eosinophilia may indicate allergic asthma; 
- renal biopsy eosinophilia may indicate drug reaction; 
- parasitic diseases such as nematode infestations and schistosomiasis are 
frequently encountered and eosinophilia is a typical hallmark of such 
infestations. 
A further possible example is that the use of Pagoda Red staining could be useful in 
evaluating oesophageal biopsies where eosinophils are searched for as an indication 
of gastro-oesophageal reflux disease.  We foresee that Pagoda Red stains may 
have useful application in other disciplines. 
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Secondly we concluded that a count of less than 10 splenic eosinophils per x40 field 
OR a MCT below 45 does NOT exclude anaphylactic death. 
 
In a small cohort (cases A, B, I etc.) IgE levels were sometimes more conclusive in 
documenting the allergic nature of the death than were splenic eosinophils or MCT 
(sample V – case 1 vide supra) and case report 2.   
 
It thus appears that the diagnosis of anaphylaxis at autopsy remains a challenge to 
the forensic pathologist. We also sound a caveat regarding the non-linearity of 
human systems [14], and we are of the opinion that this line of research involving 
MCT levels, eosinophilia and anaphylactic death should be pursued vigorously, 
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Tables for upload 
Study Sex Age Presentation 
Trigger Time  to 
death 






G F 54 Angioedema after ACE inhibitor administered. 
Known sensitive, but hospital folder was locked 
away. 
ACE inhibitor 1 hour Yes Marked oedema and pallor of tongue and 
laryngeal mucosa. Co-morbidities 
16.4 ACE 
inhibitors 









Penicillin Drug screen: 
paracetamol. 
U F 72 Chest infection Rx. Intravenous Avelon.  
Collapsed in 15 minutes.  Urticaria.  Hypoxic brain 
injury. 
Avelon IV 15 
minutes 
Yes No mucosal swelling. Subpleural 
atelectasis. . Ischaemic Heart Disease. 





18.1  PM: 
39.5 
Penicillin 
D & K F 22 Started fitting in her sleep. Unknown Unknown No No mucosal swelling.  Pulmonary TB.  
Vegetables in stomach. Multiple small pale 









R F 66 New on ACE inhibitor Rx. ACE inhibitor 
anaphylactic reaction. Hypertension  and 
Diabetes Mellitus 
ACE inhibitor unknown Yes Tongue swollen, prolapsed. Swollen face. 
General congestion. Subconjunctival 
haemorrhage. Pulmonary oedema. Airway 
mucosa swollen. Ischaemic Heart Disease 





A M 38 Aorto-iliac AS with acute leg ischaemia. 
Angiogram. Thrombectomies. Streptokinase 
administration. Immediate BP drop 
Streptokinase Immediate Yes Medical and surgical additions. Mural 
thrombus left ventricle. Extensive 
atherosclerosis. Shock kidneys. 
139 Unknown Total IgE 36kU/l 
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H M 64 Fell ill immediately after ingesting Panamor AT50 






in 4 hours 
Yes Swollen laryngeal mucosa. General 
congestion. Congested lungs, subpleural 
haemorrhages 
Ischaemic Heart Disease & Atherosclerosis 
436 Unknown   
O M 2 Betapen syrup for respiratory infection. After 
administration child felt tired and was taken to 














V M 32 Returned from night shift at fish factory.  Girlfriend 
says he stepped out of the house at 07h40. 
Found passed away outside the house at 08h00. 
? Parasite ? 
Anisakis 
Unknown No Hypertensive heart, oedematous lungs. 
Pale conjunctivae and oral mucosa.  
Laryngeal oedema not seen. 
Granulomatous lesions in the liver.  
Follicular spleen. 
28.1 NO Anisakis 
antibody weak 
positive. IgE 




urine, not in 
blood. 
E M 71 Total hip replacement. Co-morbidities: IHD with 
pacemaker. Follicular lymphoma. Obese.  
Hypotension and oliguria day after op. ARDS. 
?sepsis ?drug reaction.  Died 2 days after op. 
? Drug within 24 
hours 
Yes Heart large and flabby. Liver fatty and 
nutmeg. Shock kidneys. Spleen diffluent. 
21 Unknown   
L F 32 Septic wound hand, cellulitis whole arm.  IV 
Antibiotics and analgesics. Started 00h45.  
Cardiac arrest at 13h30.  ?Gas gangrene 
?Gas gangrene within 24 
hours 
Yes Septic wound R hand, arm swollen with 
blisters.  Pus swab: staph aureus and strep 
pyogenes. 
3.68 Unknown   
S F 88 Gradual development skin rash 2 weeks. 
Developed Toxic epidermal necrolysis, uncertain 
which drug triggered it.  Sepsis: Klebsiella, E coli, 






Yes Skin and mucosal desquamation. Mitral 
valve stenosis, Left Ventricular Hypertrophy; 
Atherosclerosis 
51 Unknown toxicology 
negative 
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B M 67 SCUBA diving accident. Drowning and injuries Drowning ±1 hour Yes Resus trauma.  Bruising caused by being 
washed onto rocks. Bruising of neck due to 
violent dragging of diving mask.  Swelling 
and bruising larynx and one vocal cord. 
Irregular aeration lungs. Bruised stomach. 




I M 69 Endoscopic eye operation.  Fatal air embolism Air embolism Immediate Yes Air embolism demonstrated by X-ray and 
PM testing. 






P F 40 Obese.  Polycystic ovarian syndrome. DM. LV 
function 47% Mitral valve replacement.  
Unsuccessful weaning from bypass.  Crashed 
after protamine.  Died on table. 
Cardiac failure Minutes Yes Advanced cardiac pathology: Hypertension; 
Atherosclerosis, Valvular heart disease. 
13.5 Unknown Protamine IgE: 
0.00kUA/l 
W M 35 Fit Nigerian soccer player. Was queuing at Home 
Affairs. Sudden collapse, grabbing his throat as if 
choking.  
HOCM Minutes No Pale conjunctiva. Pulmonary oedema. 
Enlarged heart. 
18.3 Unknown Sulfadoxine, 
possibly malaria 
prophylaxis 
F F 37 Started making funny noises in her sleep. Had 
been complaining of chest pain and shortness of 
breath. DOA 
Acute MI Minutes No Acute on chronic MI, 90% LAD occlusion. 
Tongue bitten. Pulmonary oedema. 
More than 
200 
Unknown   
M M 22 Gunshot wound through the chest GSW chest Minutes No Haemothorax: 1300 L, 900 R.  Lungs 
collapsed, pale. 
24.2 Unknown Alcohol 0.00 
T M 47 Suicide by drowning in the sea Drowning Minutes No Froth in airways. Lungs hypervoluminous, 
puffy and frothy oedema present. 
Hypertensive and atherosclerotic cardiac 
disease. 







C F 5 
months 
Sudden unexpected infant death while sleeping at 
a crèche. 




Blood culture - 
mixed growth. 
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J F 75 Descending colon and rectum resection for bowel 





5 hours Yes Sepsis, DIC 67.6 Unknown   
Q M 28 Still's disease, haemophagocytic 





1 day Yes Bronchopneumonia, hypercellular bone 




X M 5 
months 
Sudden unexpected infant death while sleeping at 




upper and lower 
respiratory tract 
infection. 
Minutes No Dark, puffy lungs. 52.6     
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Sample Case Number Diagnosis Cause of death Mast Cell 
Reference Tryptase 
Level 
A DR 2046/2006 Anaphylaxis Streptokinase allergic reaction 139 
D * DR 313/2006 block 6 Anaphylaxis Unknown 21 
G DR 1520/2002 Anaphylaxis ACE inhibitor reaction 16.4 
H WC 11/1548/2007 Anaphylaxis Panamor [Diclofenac p.o.] reaction 436 
K * DR 313/2006 block 7 Anaphylaxis Unknown 21 
N DR 830/2005 Anaphylaxis 
Tramacet [tramadol/Paracetamol p.o.] 
reaction 19.5 
O WC 11/676/2011 Anaphylaxis Betapen [penicillin p.o.]- penicillin allergy 1530 
R DR 359/2006 Anaphylaxis ACE inhibitor reaction 539 
U DR 982/2005 Anaphylaxis Avelon IV [Moxifloxacin] -reaction to 39.5 
V WC 11/873/2013 Anaphylaxis Nematode infestation - possibly Anasakis 28.1 
B WC 11/2712/2008 Control Drowning at sea 13.4 
E DR 2032/2002 Control Sepsis 21 
F WC 11/1348/2012 Control Acute MI 200 + 
I WC 11/2385/2009 Control Air embolism during surgery 14.1 
L DR 827/2005 Control Gas gangrene 3.68 
M WC 11/1372/2012 Control Gunshot chest 24.2 
P WC 11/1325/2011 Control IHD & valvular heart disease 13.5 
S DR 2147/2006 Control Toxic epidermal necrolysis 51 
T WC 11/1670/2012 Control Drowning at sea 28.4 
W WC 11/720/2012 Control Hypertrophic obstructive cardiomyopathy 18.3 
C WC 11/1389/2012 Sec. Control Bronchiolitis 17.2 
J WC 11/1452/2012 Sec. Control Sepsis 67.6 
Q WC 11/1456/2012 Sec. Control Septic Shock 12.7 
X WC 11/1628/2012 Sec. Control Bronchiolitis 52.6 
Table 2. Key to samples with abbreviated diagnoses, MCT levels and case numbers 
Asterisked samples represent two different sections of spleen from the same case 




Inexperienced Analyst "PB" 
Diagnosis Sample H&E Magenta. Pagoda 
Red 
H&E Magenta Pagoda  
Red 
Abbreviated diagnosis 
Anaphylaxis A 87 19 20 90 34 28 Drug reaction- Streptokinase 
Anaphylaxis D 32 7 2 2 2 0 Unknown 
Anaphylaxis G 29 29 66 54 61 82 Drug reaction -ACE inhibitor 
Anaphylaxis H 23 6 3 2 3 10 Drug reaction- Diclofenac 
Anaphylaxis K 24 13 37 16 14 15 Unknown 
Anaphylaxis N 128 31 33 11 8 16 Drug reaction -Paracetamol/Tramadol  
Anaphylaxis O 79 83 92 41 23 28 Drug reaction - Penicillin 
Anaphylaxis R 10 9 2 20 12 0 Drug reaction -ACE inhibitor 
Anaphylaxis U 38 2 45 36 21 19 Drug reaction - Moxifloxacin 
Anaphylaxis V 484 413 537 226 221 181 Nematode infestation - ? Anasakis  
Control B 19 13 15 52 31 55 Drowning at sea 
Control C 64 29 67 33 33 71 Bronchiolitis 
Control E 124 23 4 10 4 6 Sepsis 
Control F 92 22 23 116 69 24 Acute MI 
Control I 9 0 20 3 0 27 Air embolism during surgery 
Control J 20 5 8 24 0 0 Sepsis 
Control L 45 7 1 2 1 0 Gas Gangrene 
Control M 38 32 53 24 10 34 Gunshot wound - chest 
Control P 62 31 25 55 72 6 IHD & valvular heart disease 
Control Q 25 15 18 9 13 12 Septic Shock 
Control S 23 7 15 6 15 8 Toxic epidermal necrolysis 
Control T 25 9 13 61 37 8 Drowning at sea 
Control W 118 92 195 42 14 52 Hypertrophic obstructive cardiomyopathy 
Control X 91 59 83 31 20 25 Bronchiolitis 
Table 3. Table of total cell counts in ten 40x fields, per sample, per analyst, per stain, plus 
abbreviated diagnosis 





Stains compared P values Stain exhibiting the 
Highest cell count 
A Anaphylaxis H&E vs Pagoda Red 0.0022 H&E 
D Anaphylaxis H&E vs Magenta 0.0015 H&E 
D Anaphylaxis H&E vs Pagoda Red 0.0001 H&E 
G Anaphylaxis H&E vs Pagoda Red 0.0042 Pagoda Red 
G Anaphylaxis Magenta vs Pagoda Red 0.0074 Pagoda Red 
H Anaphylaxis H&E vs Magenta 0.0011 H&E 
H Anaphylaxis H&E vs Pagoda Red 0.0006 H&E 
K Anaphylaxis H&E vs Pagoda Red 0.0484 Pagoda Red 
K Anaphylaxis Magenta vs Pagoda Red 0.0011 Pagoda Red 
N Anaphylaxis H&E vs Magenta 0.0003 H&E 
N Anaphylaxis H&E vs Pagoda Red 0.0002 H&E 
R Anaphylaxis H&E vs Pagoda Red 0.0017 H&E 
R Anaphylaxis Magenta vs Pagoda Red 0.0017 Magenta 
C Control H&E vs Magenta 0.0026 H&E 
C Control Magenta vs Pagoda Red 0.0034 Pagoda Red 
E Control H&E vs Magenta 0.0002 H&E 
E Control H&E vs Pagoda Red 0.0001 H&E 
E Control Magenta vs Pagoda Red 0.0034 Magenta 
F Control H&E vs Magenta 0.0003 H&E 
F Control H&E vs Pagoda Red 0.0003 H&E 
I Control H&E vs Pagoda Red 0.0242 Pagoda Red 
I Control Magenta vs Pagoda Red 0.0002 Pagoda Red 
J Control H&E vs Magenta 0.0454 H&E 
J Control H&E vs Pagoda Red 0.0401 H&E 
L Control H&E vs Magenta 0.0002 H&E 
L Control H&E vs Pagoda Red 0.0001 H&E 
L Control Magenta vs Pagoda Red 0.0212 H&E 
M Control Magenta vs Pagoda Red 0.0129 Pagoda Red 
P Control H&E vs Magenta 0.0091 H&E 
P Control H&E vs Pagoda Red 0.0035 H&E 
S Control H&E vs Magenta 0.0027 H&E 
T Control H&E vs Magenta 0.0093 Pagoda Red 
W Control H&E vs Pagoda Red 0.0028 Pagoda Red 
W Control Magenta vs Pagoda Red 0.006 Pagoda Red 
X Control H&E vs Magenta 0.0202 H&E 
Table 4: Showing statistically significant comparison cell counts by the experienced analyst, per stain 






Stains compared P values Stain exhibiting the 
Highest cell count 
R Anaphylaxis H&E vs Pagoda Red 0.0019 H&E 
R Anaphylaxis Magenta vs Pagoda Red 0.0049 Magenta 
V Anaphylaxis H&E vs Magenta 0.0311 H&E 
C Control H&E vs Pagoda Red 0.0192 Pagoda Red 
C Control Magenta vs Pagoda Red 0.0361 Pagoda Red 
F Control H&E vs Magenta 0.0301 H&E 
F Control Magenta vs Pagoda Red 0.0017 Magenta 
I Control H&E vs Pagoda Red 0.0006 Pagoda Red 
I Control Magenta vs Pagoda Red 0.0002 Pagoda Red 
J Control H&E vs Magenta 0.0024 H&E 
J Control H&E vs Pagoda Red 0.0002 H&E 
M Control Magenta vs Pagoda Red 0.0078 Pagoda Red 
P Control H&E vs Pagoda Red 0.0001 H&E 
P Control Magenta vs Pagoda Red 0.0001 Magenta 
T Control H&E vs Pagoda Red 0.0018 H&E 
W Control Magenta vs Pagoda Red 0.0025 Pagoda Red 
 













H&E sample cases 9.34 4 14.33 0-71 
H&E control cases 5.22 4 4.601 0-21 
Magenta sample cases 6.02 2 13.08 0-73 
Magenta control cases 2.46 2 2.95 0-17 
Pagoda Red sample cases 3.71 3 5.35 0-46 
Pagoda Red control cases 3.86 2 6.16 0-37 
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Inexperienced Analyst 
"PB" 







H&E sample cases 4.98 2 7.82 0-33
H&E control cases 3.34 2 4.58 0-27
Magenta sample cases 3.99 1 7.03 0-34
Magenta control cases 2.27 1 3.59 0-21
Pagoda Red sample cases 3.8 1 5.79 0-28
Pagoda Red control cases 2.34 1 3.52 0-28
Table 7: Mean cell counts per stain for the inexperienced analyst 
References 
1. Shen, Y., Li, L., Grant, J., Rubio, A., Zhao, Z., Zhang, X., Zhou, L. & Fowler, D.
2009. Anaphylactic deaths in Maryland (United States) and Shanghai (China): a
review of forensic autopsy cases from 2004 to 2006.  Forensic Science
International.186 (1-3):1-5. DOI:10.1016/j.forsciint.2008.12.007 [doi].
2. Pumphrey, R.S. & Roberts, I.S. 2000.Postmortem findings after fatal anaphylactic
reactions.  Journal of Clinical Pathology.53 (4):273-276.
3. Da Broi, U. &Moreschi, C. 2011. Post-mortem diagnosis of anaphylaxis: A difficult
task in forensic medicine.  Forensic Science International.204 (1-3):1-5.
DOI:10.1016/j.forsciint.2010.04.039 [doi].
4. Delage, C. &Irey, N.S. 1972. Anaphylactic deaths: a clinicopathologic study of 43
cases.  Journal of Forensic Sciences.17 (4):525-540.
5. Perskvist, N. &Edston, E. 2007. Differential accumulation of pulmonary and
cardiac mast cell-subsets and eosinophils between fatal anaphylaxis and asthma
death: a postmortem comparative study. Forensic Science International.
169(1):43-49. DOI: S0379-0738(06)00530-5 [pii].
6. Edston, E. 2013.Accumulation of eosinophils, mast cells, and basophils in the
spleen in anaphylactic deaths.  Forensic Science, Medicine, and Pathology.9
(4):496-500. DOI: 10.1007/s12024-013-9468-9 [doi].
P a g e  | 70 
7. Trani, N., Bonetti, L.R., Gualandri, G. &Barbolini, G. 2008. Immediate
anaphylactic death following antibiotics injection: splenic eosinophilia easily
revealed by pagoda red stain.  Forensic Science International.181 (1-3):21-25.
DOI:10.1016/j.forsciint.2008.08.011 [doi].
8. Schwartz, L.B. 2006.Diagnostic value of tryptase in anaphylaxis and
mastocytosis.  Immunology and Allergy Clinics of North America.26 (3):451-463.
DOI: S0889-8561(06)00057-9 [pii].
9. Osawa, M., Satoh, F., Horiuchi, H., Tian, W., Kugota, N. & Hasegawa, I.
2008.Postmortem diagnosis of fatal anaphylaxis during intravenous
administration of therapeutic and diagnostic agents: Evaluation of clinical
laboratory parameters and immunohistochemistry in three cases.  Legal
Medicine.10 (3):143-147. DOI:http://dx.doi.org/10.1016/j.legalmed.2007.10.002
10. Schwartz, L.B., Sakai, K., Bradford, T.R., Ren, S., Zweiman, B., Worobec, A.S.
&Metcalfe, D.D. 1995. The alpha form of human tryptase is the predominant type
present in blood at baseline in normal subjects and is elevated in those with
systemic mastocytosis. The Journal of Clinical Investigation. 96(6):2702-2710.
DOI: 10.1172/JCI118337 [doi].
11. Edston, E. & van Hage-Hamsten, M. 1998. beta-Tryptase measurements post-
mortem in anaphylactic deaths and in controls.  Forensic Science International.93
(2-3):135-142. DOI: S0379-0738(98)00040-1 [pii].
12. Edston, E., Eriksson, O. & van Hage, M. 2007. Mast cell tryptase in postmortem
serum-reference values and confounders.  International Journal of Legal
Medicine.121 (4):275-280. DOI: 10.1007/s00414-006-0101-2 [doi].
13. Reggiani Bonetti, L., Maccio, L., Trani, N., Radheshi, E. &Palmiere, C. 2014.
Splenic hypereosinophilia in anaphylaxis-related death: different assessments
depending on different types of allergens?  International Journal of Legal
Medicine.DOI:10.1007/s00414-014-1004-2 [doi].
14. Jones, R.M. 2015.Complexity and forensic pathology.  Forensic Science
International.257:e38-43. DOI:10.1016/j.forsciint.2015.08.026 [doi].
15. Kounis, N.G., Soufras, G.D. &Hahalis, G. 2014. Accumulation of eosinophils,
mast cells, and basophils in the spleen and the coronary arteries in anaphylactic
deaths: is the Kounis hypersensitivity associated syndrome present?  Forensic
Science, Medicine, and Pathology.10 (1):150-151. DOI: 10.1007/s12024-013-
P a g e  | 71 
9489-4 [doi]. 
16. Kounis, N.G., Davlouros, P., Hahalis, G. &Mazarakis, A. 2012. The heart seems
to be the primary site and the target of anaphylaxis resulting in the development
of Kounis syndrome.  Internal and Emergency Medicine.7 Suppl 2:S119-20. DOI:
10.1007/s11739-012-0786-9 [doi].
17. Kounis, N.G., Tsigkas, G., Almpanis, G., Kouni, S.N., Kounis, G.N. &Mazarakis,
A. 2011b. Anaphylaxis-induced hyperfibrinogenolysis and the risk of Kounis
syndrome: the dual action of tryptase.  The American Journal of Emergency
Medicine.29 (9):1229-1230. DOI:10.1016/j.ajem.2011.06.002 [doi].
18. Kounis, N.G., Mazarakis, A., Tsigkas, G., Giannopoulos, S. &Goudevenos, J.
2011a.Kounis syndrome: a new twist on an old disease.  Future Cardiology.7
(6):805-824. DOI:10.2217/fca.11.63 [doi].
P a g e  | 72 
PART D: APPENDICES 
Acknowledgments 
The significant contributions made by the following persons, without whose 
assistance, advice, and active participation this study would not have been possible 
are acknowledged: 
Dr. L. Liebenberg, Dept. of Clinical Laboratory Sciences; Division of 
Forensic Medicine, University of Cape Town Health 
Sciences Faculty, who as my supervisor had the 
unenviable task of ploughing her way through the 
plethora of submissions, revisions, and drafts of the prose 
sections of the study, the many spreadsheets of data, 
and who spent innumerable hours peering at the stained 
sections of tissue emanating from this study, counting 
eosinophils!. 
Ms. M. Perrins; Dept. of Clinical Laboratory Sciences; Division of 
Forensic Medicine, University of Cape Town Health 
Sciences Faculty, who kept a close eye on the 
preparation of the slides for examination, and 
enthusiastically supported the project. 
Ms. Y. Davis; Dept. of Clinical Laboratory Sciences; Division of 
Forensic Medicine, University of Cape Town Health 
Sciences Faculty, who spent countless hours researching 
and developing a suitable method for the staining of the 
P a g e  | 73 
samples with the Magenta Dye, and who prepared the 
individual slides used in the study; and on her own 
initiative sought out control samples of tissue to verify the 
staining process. 
Spotless Punch PLC: The proprietors and manufacturers of DylonTM Pagoda 
Red dye, for providing free of charge sufficient Pagoda 
Red dye for the completion of the study. 
Mr. Calvin Mole: From the Division of Forensic Medicine, who performed 
the statistical calculations? 
References 
Battaglia, S., Barbolini, G., Botticelli, A.R. &Trentini, G.P. 1985. Apoptotic amyloid: a 
study on prostatic amyloidosis with particular reference to corpora 
amylacea.  Applied Pathology.3 (1-2):105-114. 
Bennich, H., Ishizaka, K., Ishizaka, T. & Johansson, S.G. 1969.A comparative 
antigenic study of gamma E-globulin and myeloma-IgND.  Journal of 
Immunology (Baltimore, Md.: 1950).102(4):826-831. 
Blank, U., Ra, C., Miller, L., White, K., Metzger, H. &Kinet, J.P. 1989.Complete 
structure and expression in transfected cells of high affinity IgE 
receptor.  Nature.337 (6203):187-189. DOI: 10.1038/337187a0 [doi]. 
Bochner, B.S. & Lichtenstein, L.M. 1991.Anaphylaxis.  The New England Journal of 
Medicine.324 (25):1785-1790. DOI: 10.1056/NEJM199106203242506 [doi]. 
Da Broi, U. &Moreschi, C. 2011. Post-mortem diagnosis of anaphylaxis: A difficult 
task in forensic medicine.  Forensic Science International.204 (1-3):1-5. 
DOI:10.1016/j.forsciint.2010.04.039 [doi]. 
Dale, H.H. & Laidlaw, P.P. 1910. The physiological action of beta-
iminazolylethylamine.  The Journal of Physiology.41 (5):318-344. 
Delage, C. &Irey, N.S. 1972. Anaphylactic deaths: a clinicopathologic study of 43 
cases.  Journal of Forensic Sciences.17 (4):525-540. 
Edston, E. 2013.Accumulation of eosinophils, mast cells, and basophils in the spleen 
in anaphylactic deaths.  Forensic Science, Medicine, and Pathology.9 (4):496-
500. DOI: 10.1007/s12024-013-9468-9 [doi].
P a g e  | 74 
Edston, E., Eriksson, O. & van Hage, M. 2007. Mast cell tryptase in postmortem 
serum-reference values and confounders.  International Journal of Legal 
Medicine.121 (4):275-280. DOI: 10.1007/s00414-006-0101-2 [doi]. 
Edston, E. & van Hage-Hamsten, M. 1998. beta-Tryptase measurements post-
mortem in anaphylactic deaths and in controls.  Forensic Science 
International.93 (2-3):135-142. DOI: S0379-0738(98)00040-1 [pii]. 
Edston, E. & van Hage-Hamsten, M. 2003. Mast cell tryptase and hemolysis after 
trauma.  Forensic Science International.131 (1):8-13. DOI: S0379073802003833 
[pii]. 
Evans, D.P. & Thomson, D.S. 1972. Histamine release from rat mast cells passively 
sensitised with homocytotropic (IgE) antibody.  International Archives of Allergy 
and Applied Immunology.43 (2):217-231. 
Fineschi, V., Cecchi, R., Centini, F., Reattelli, L.P. &Turillazzi, E. 
2001.Immunohistochemical quantification of pulmonary mast-cells and post-
mortem blood dosages of tryptase and eosinophil cationic protein in 48 heroin-
related deaths.  Forensic Science International.120 (3):189-194. DOI: 
S0379073800004692 [pii]. 
Fisher, M.M. &Baldo, B.A. 1998. Mast cell tryptase in anaesthetic anaphylactoid 
reactions.  British Journal of Anaesthesia.80 (1):26-29. 
Garman, S.C., Kinet, J.P. &Jardetzky, T.S. 1998.Crystal structure of the human high-
affinity IgE receptor.  Cell.95 (7):951-961. DOI: S0092-8674(00)81719-5 [pii]. 
Gleich, G.J. &Adolphson, C.R. 1986. The eosinophilic leukocyte: structure and 
function.  Advances in Immunology.39:177-253. 
Gounni, A.S., Lamkhioued, B., Ochiai, K., Tanaka, Y., Delaporte, E., Capron, A., 
Kinet, J.P. & Capron, M. 1994. High-affinity IgE receptor on eosinophils is 
involved in defence against parasites.  Nature.367 (6459):183-186. DOI: 
10.1038/367183a0 [doi]. 
Gouon-Evans, V., Rothenberg, M.E. & Pollard, J.W. 2000. Postnatal mammary gland 
development requires macrophages and eosinophils.  Development (Cambridge, 
England).127(11):2269-2282. 
Horn, K.D., Halsey, J.F. &Zumwalt, R.E. 2004.Utilization of serum tryptase and 
immunoglobulin e assay in the postmortem diagnosis of anaphylaxis.  The 
American Journal of Forensic Medicine and Pathology.25 (1):37-43. DOI: 
00000433-200403000-00008 [pii]. 
Humbles, A.A., Lu, B., Friend, D.S., Okinaga, S., Lora, J., Al-Garawi, A., Martin, 
T.R., Gerard, N.P. et al. 2002. The murine CCR3 receptor regulates both the
role of eosinophils and mast cells in allergen-induced airway inflammation and
hyperresponsiveness.  Proceedings of the National Academy of Sciences of the
United States of America.99 (3):1479-1484. DOI:10.1073/pnas.261462598 [doi].
Ishizaka, K., Ishizaka, T. &Hornbrook, M.M. 1966.Physicochemical properties of 
reaginic antibody. V. Correlation of reaginic activity with gamma-E-globulin 
antibody.  Journal of Immunology (Baltimore, Md.: 1950).97(6):840-853. 
Johansson, S.G. &Bennich, H. 1967. Immunological studies of an atypical 
(myeloma) immunoglobulin.  Immunology.13 (4):381-394. 
Jonsson, F. &Daeron, M. 2012.Mast cells and company.  Frontiers in 
Immunology.3:16. DOI:10.3389/fimmu.2012.00016 [doi]. 
P a g e  | 75 
Jonsson, F., Mancardi, D.A., Kita, Y., Karasuyama, H., Iannascoli, B., Van Rooijen, 
N., Shimizu, T., Daeron, M. et al. 2011. Mouse and human neutrophils induce 
anaphylaxis.  The Journal of Clinical Investigation.121 (4):1484-1496. DOI: 
10.1172/JCI45232 [doi]. 
Khan, N.U., Shakeel, N., Makda, A., Mallick, A.S., Ali Memon, M., Hashmi, S.H., 
Khan, U.R. &Razzak, J.A. 2013. Anaphylaxis: incidence, presentation, causes 
and outcome in patients in a tertiary-care hospital in Karachi, Pakistan.  QJM: 
Monthly Journal of the Association of Physicians. 106(12):1095-1101. 
DOI:10.1093/qjmed/hct179 [doi]. 
Knight, B., Forensic Pathology, Second edition; Oxford University Press, 1996; New 
York. 
Kounis, N.G. 2013. Hymenoptera stings, anaphylactic shock and the kounis 
syndrome.  North American Journal of Medical Sciences.5 (2):159-160. 
DOI:10.4103/1947-2714.107545 [doi]. 
Kounis, N.G., Davlouros, P., Hahalis, G. &Mazarakis, A. 2012. The heart seems to 
be the primary site and the target of anaphylaxis resulting in the development of 
Kounis syndrome.  Internal and Emergency Medicine.7 Suppl 2:S119-20. DOI: 
10.1007/s11739-012-0786-9 [doi]. 
Kounis, N.G., Mazarakis, A., Tsigkas, G., Giannopoulos, S. &Goudevenos, J. 
2011a.Kounis syndrome: a new twist on an old disease.  Future Cardiology.7 
(6):805-824. DOI:10.2217/fca.11.63 [doi]. 
Kounis, N.G., Soufras, G.D. &Hahalis, G. 2014. Accumulation of eosinophils, mast 
cells, and basophils in the spleen and the coronary arteries in anaphylactic 
deaths: is the Kounis hypersensitivity associated syndrome present?  Forensic 
Science, Medicine, and Pathology.10 (1):150-151. DOI: 10.1007/s12024-013-
9489-4 [doi]. 
Kounis, N.G., Tsigkas, G., Almpanis, G., Kouni, S.N., Kounis, G.N. &Mazarakis, A. 
2011b. Anaphylaxis-induced hyperfibrinogenolysis and the risk of Kounis 
syndrome: the dual action of tryptase.  The American Journal of Emergency 
Medicine.29 (9):1229-1230. DOI:10.1016/j.ajem.2011.06.002 [doi]. 
Kiyono, J., Tada, T., Wakabayashi, T., Kishimoto, H. & Nitta, M. 1982.Eosinophile 
granule staining with Dylon.  Rinsho Byori. The Japanese Journal of Clinical 
Pathology.30 (10):1137-1141. 
Kulczycki, A., Jr, Isersky, C. & Metzger, H. 1974. The interaction of IgE with rat 
basophilic leukemia cells. I. Evidence for specific binding of IgE.  The Journal of 
Experimental Medicine.139 (3):600-616. 
Lowell, C.A. 2011. Neutrophils give us a shock.  The Journal of Clinical 
Investigation.121 (4):1260-1263. DOI: 10.1172/JCI57296 [doi]. 
Marone, G., de Crescenzo, G., Florio, G., Granata, F., Dente, V. & Genovese, A. 
1999.Immunological modulation of human cardiac mast cells.  Neurochemical 
Research. 24(9):1195-1202. 
Marone, G., Genovese, A., Varricchi, G. &Granata, F. 2014.Human heart as a shock 
organ in anaphylaxis.  Allergo Journal International.23 (2):60-66. DOI: 
10.1007/s40629-014-0007-3 [doi]. 
Maurer, U., Kager, C., Fellinger, C., Loader, D., Pollesbock, A., Spitzer, B. &Jarisch, 
R. 2014. Risk of anaphylaxis in opioid dependent persons: effects of heroin 
P a g e  | 76 
versus substitution substance.  Substance Abuse Treatment, Prevention, and 
Policy.9:12-597X-9-12. DOI: 10.1186/1747-597X-9-12 [doi]. 
Mayer, D.E., Krauskopf, A., Hemmer, W., Moritz, K., Jarisch, R. & Reiter, C. 2011. 
Usefulness of post mortem determination of serum tryptase, histamine and 
diamine oxidase in the diagnosis of fatal anaphylaxis.  Forensic Science 
International.212 (1–3):96-101. DOI: 
http://dx.doi.org/10.1016/j.forsciint.2011.05.020. 
Mishra, A., Hogan, S.P., Lee, J.J., Foster, P.S. & Rothenberg, M.E. 
1999.Fundamental signals that regulate eosinophil homing to the gastrointestinal 
tract.  The Journal of Clinical Investigation.103 (12):1719-1727. DOI: 
10.1172/JCI6560 [doi]. 
Nishio, H., Takai, S., Miyazaki, M., Horiuchi, H., Osawa, M., Uemura, K., Yoshida, 
K., Mukaida, M. et al. 2005. Usefulness of serum mast cell-specific chymase 
levels for postmortem diagnosis of anaphylaxis.  International Journal of Legal 
Medicine.119 (6):331-334. DOI: 10.1007/s00414-005-0524-1 [doi]. 
Osawa, M., Satoh, F., Horiuchi, H., Tian, W., Kugota, N. & Hasegawa, I. 
2008.Postmortem diagnosis of fatal anaphylaxis during intravenous 
administration of therapeutic and diagnostic agents: Evaluation of clinical 
laboratory parameters and immunohistochemistry in three cases.  Legal 
Medicine.10 (3):143-147. DOI: http://dx.doi.org/10.1016/j.legalmed.2007.10.002. 
Payne, V. &Kam, P.C. 2004. Mast cell tryptase: a review of its physiology and clinical 
significance.  Anaesthesia.59 (7):695-703. DOI:10.1111/j.1365-
2044.2004.03757.x [doi]. 
Pope, S.M., Fulkerson, P.C., Blanchard, C., Akei, H.S., Nikolaidis, N.M., 
Zimmermann, N., Molkentin, J.D. & Rothenberg, M.E. 2005.Identification of a 
cooperative mechanism involving interleukin-13 and eotaxin-2 in experimental 
allergic lung inflammation.  The Journal of Biological Chemistry.280 (14):13952-
13961. DOI: M406037200 [pii]. 
Prouvost-Danon, A., Javierre, M.Q. & Lima, M.S. 1966.Passive anaphylactic reaction 
in mouse peritoneal mast cells in vitro.  Life Sciences.5 (19):1751-1760. 
Randall, B., Butts, J. & Halsey, J.F. 1995.Elevated postmortem tryptase in the 
absence of anaphylaxis.  Journal of Forensic Sciences.40 (2):208-211. 
Reggiani Bonetti, L., Maccio, L., Trani, N., Radheshi, E. &Palmiere, C. 2014. Splenic 
hypereosinophilia in anaphylaxis-related death: different assessments 
depending on different types of allergens?  International Journal of Legal 
Medicine.DOI:10.1007/s00414-014-1004-2 [doi]. 
RILEY, J.F. 1953. Histamine in tissue mast cells.  Science (New York, N.Y.). 
118(3064):332. 
Sampson, H.A., Munoz-Furlong, A., Campbell, R.L., Adkinson, N.F.,Jr, Bock, S.A., 
Branum, A., Brown, S.G., Camargo, C.A.,Jr et al. 2006. Second symposium on 
the definition and management of anaphylaxis: summary report--Second 
National Institute of Allergy and Infectious Disease/Food Allergy and 
Anaphylaxis Network symposium.  The Journal of Allergy and Clinical 
Immunology.117 (2):391-397. DOI: S0091-6749(05)02723-5 [pii]. 
Scarlet, C. 2006.Anaphylaxis.  Journal of Infusion Nursing: The Official Publication of 
the Infusion Nurses Society. 29(1):39-44. DOI: 00129804-200601000-00008 
[pii]. 
P a g e  | 77 
Schwartz, L.B. 2006.Diagnostic value of tryptase in anaphylaxis and 
mastocytosis.  Immunology and Allergy Clinics of North America.26 (3):451-463. 
DOI: S0889-8561(06)00057-9 [pii]. 
Schwartz, L.B., Yunginger, J.W., Miller, J., Bokhari, R. & Dull, D. 1989.Time course 
of appearance and disappearance of human mast cell tryptase in the circulation 
after anaphylaxis.  The Journal of Clinical Investigation.83 (5):1551-1555. DOI: 
10.1172/JCI114051 [doi]. 
Seminario, M.C., Saini, S.S., MacGlashan, D.W., Jr & Bochner, B.S. 1999. 
Intracellular expression and release of Fc epsilon RI alpha by human 
eosinophils.  Journal of Immunology (Baltimore, Md.: 1950).162(11):6893-6900. 
Shanmugam, G., Schwartz, L.B. & Khan, D.A. 2006.Prolonged elevation of serum 
tryptase in idiopathic anaphylaxis.  The Journal of Allergy and Clinical 
Immunology.117 (4):950-951. DOI: S0091-6749(06)00180-1 [pii]. 
Shen, Y., Li, L., Grant, J., Rubio, A., Zhao, Z., Zhang, X., Zhou, L. & Fowler, D. 2009. 
Anaphylactic deaths in Maryland (United States) and Shanghai (China): a review 
of forensic autopsy cases from 2004 to 2006.  Forensic Science 
International.186 (1-3):1-5. DOI:10.1016/j.forsciint.2008.12.007 [doi]. 
Stone, S.F. & Brown, S.G. 2012. Mediators released during human 
anaphylaxis.  Current Allergy and Asthma Reports.12 (1):33-41. DOI: 
10.1007/s11882-011-0231-6 [doi]. 
Trani, N., Bonetti, L.R., Gualandri, G. &Barbolini, G. 2008. Immediate anaphylactic 
death following antibiotics injection: splenic eosinophilia easily revealed by 
pagoda red stain.  Forensic Science International.181 (1-3):21-25. 
DOI:10.1016/j.forsciint.2008.08.011 [doi]. 
Truong, M.J., Gruart, V., Liu, F.T., Prin, L., Capron, A. & Capron, M. 1993. IgE-
binding molecules (Mac-2/epsilon BP) expressed by human eosinophils. 
Implication in IgE-dependent eosinophil cytotoxicity.  European Journal of 
Immunology.23 (12):3230-3235. DOI:10.1002/eji.1830231228 [doi]. 
Walther, A. &Bottiger, B.W. 2004.Out-of-Hospital treatment of anaphylactoid 
reactions.  Der Internist. 45(3):296-304. DOI: 10.1007/s00108-003-1142-y [doi]. 
Yanagihara, M., Mehregan, A.H. &Mehregan, D.R. 1984.Staining of amyloid with 








P a g e  | 78 
Sundry Tables and Data 
 
      
   Anaphylaxis 16.4   
   Anaphylaxis 19.5   
   Anaphylaxis 21   
   Anaphylaxis 21   
   Anaphylaxis 28.1   
   Anaphylaxis 39.5   
   Anaphylaxis 139   
   Anaphylaxis 436   
   Anaphylaxis 539   
   Anaphylaxis 1530   
     
 
  
   Mean 278.95   
   Median 33.8   
     
 
  
   Control 3.68   
   Control 13.4   
   Control 13.5   
   Control 14.1   
   Control 18.3   
   Control 21   
   Control 24.2   
   Control 28.4   
   Control 51   
   Control 200   
   Control 12.7   
   Control 17.2   
   Control 52.6   
   Control 67.6   
     
 
  
   Mean 38.40571   
   Median 19.65   
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Analyst “LL”   
 
Inexperienced 
analyst “PB”   
   H&E Mag P.R. 
 
H&E Mag. P.R. 
 Anaphylaxis 87 20 19 
 
90 28 34   
Anaphylaxis 32 2 7 
 
2 0 2   
Anaphylaxis 29 66 29 
 
54 82 61   
Anaphylaxis 23 4 6 
 
2 10 3   
Anaphylaxis 24 37 13 
 
16 15 14   
Anaphylaxis 128 32 31 
 
11 16 8   
Anaphylaxis 79 99 83 
 
41 28 23   
Anaphylaxis 10 0 9 
 
20 0 12   
Anaphylaxis 38 45 0 
 
74 64 21   
Anaphylaxis         226 181 221   
       
    
Mean 50 33.9 21.9 
 
53.6 42.4 39.9   
Median 32 32 13 
 
30.5 22 17.5   
                  
Control 19 15 13 
 
52 55 31   
Control 128 4 23 
 
10 6 4   
Control 87 23 22 
 
116 24 69   
Control 9 20 0 
 
3 27 0   
Control 45 1 7 
 
2 0 1   
Control 38 53 32 
 
24 34 10   
Control 62 25 31 
 
55 6 72   
Control 21 16 7 
 
6 8 15   
Control 25 13 9 
 
69 21 46   
Control 118 193 92   42 52 14   
       
  
 Mean 55.2 36.3 23.6 
 
37.9 23.3 26.2 
 Median 41.5 18 17.5 
 
33 22.5 14.5 
                 
 Control 64 67 29 
 
33 71 33   
Control 17 8 5 
 
24 0 4   
Control 25 18 15 
 
9 12 13   
Control 91 94 59   31 25 20   
        
  
Mean 49.3 46.8 27 
 
24.3 27 17.5   
Median 44.5 42.5 22 
 
27.5 18.5 16.5   
                
 
         
Table of Cell counts per stain, per Analyst, Anaphylaxis versus controls 
[Used for Statistical analysis: Wilcoxon Rank Sum test] 







ref. Comments Cell Count 
Cell 
Count Sample Key 
    PB LL   
AH Autolytic 90 87 Anaphylaxis 
AM   34 19   
AP   28 20   
BH Follicular 52 19 Control 
BM   31 13   
BP   55 15   
CH Fragmentation 33 64  Control 
CM 
 
33 29   
CP   71 67   
DH Well preserved 2 32 Anaphylaxis 
DM 
 
2 7   
DP   0 2   
EH Autolytic 10 128 Control 
EM 
 
4 23   
EP   6 4   
FH Congested ++ 116 87 Control 
FM 
 
69 22   
FP   24 23   
GH Hyperaemic; Beautiful pagoda 54 29 Anaphylaxis 
GM 
 
61 29   
GP   82 66   
HH Follicular, Polis ++ cellular ++ 2 23 Anaphylaxis 
HM 
 
3 6   
HP   10 4   
IH Congestion +++,inactive white pulp 3 9 Control 
IM 
 
0 0   
IP   27 20   
JH Pale Diffluent Autolytic 24 17  Control 
JM 
 
4 5   
JP   0 8   
KH Hyperaemic, Pale 16 24 Anaphylaxis 
KM 
 
14 13   
KP   15 37   
LH Congested  2 45 Control 
LM Nuclei of possible eos stain red 1 7   
LP   0 1   
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MH Very reactive, cellular 24 38 Control 
MM 
 
10 32   
MP   34 53   
NH Very crowded, Reactive, Congested 11 128 Anaphylaxis 
NM Cell counts difficult due to ++ cellularity 8 31   
NP   16 32   
OH Follicular 41 79 Anaphylaxis 
OM 
 
23 83   
OP   28 99   
PH 
Congested; Autolytic; Non-reactive.  Poor 
staining 55 62 Control 
PM 
 
72 31   
PP   6 25   
QH Extreme congestion ; small follicles  - 9 25  Control 
QM 
 
13 15   
QP   12 18   
RH 
Moderate  Autolysis ; bacteria ++; Poor 
staining 20 10 Anaphylaxis 
RM 
 
12 9   
RP   0 0   
SH Well preserved; Follicular;  Congested 6 21 Control 
SM 
 
15 7   
SP   8 16   
TH Very cellular Polis ++ 69 25 Control 
TM 
 
46 9   
TP   21 13   
UH well preserved, Congested. Mod reactive 74 38 Anaphylaxis 
UM 
 
21 0   
UP   64 45   
VH well preserved, extremely cellular 226 484 Anaphylaxis 
VM 
 
221 413   
VP   181 537   
WH Congested, Diffluent 42 118 Control 
WM 
 
14 92   
WP   52 193   
XH Very Reactive, follicles, pale  staining 31 91  Control 
XM 
 
20 59   
XP   25 84   
 
Table of pathologist’s comments per study slide examined, plus cell counts per 10 fields per analyst. 
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Sample Description Case Number 
      
A Anaphylaxis DR 2046/2006 
D Anaphylaxis DR 313/2006 
G Anaphylaxis DR 1520/2002 
H Anaphylaxis WC 11/1548/2007 
K Anaphylaxis DR 313/2006 
N Anaphylaxis DR 830/2005 
O Anaphylaxis WC 11/676/2011 
R Anaphylaxis DR 359/2006 
U Anaphylaxis DR 982/2005 
V Anaphylaxis WC 11/873/2013 
B Control WC 11/2712/2008 
C Control WC 11/1389/2012 
E Control DR 2032/2002 
F Control WC 11/1348/2012 
I Control WC 11/2385/2009 
J Control WC 11/1452/2012 
L Control DR 827/2005 
M Control WC 11/1372/2012 
P Control WC 11/1325/2011 
Q Control WC 11/1456/2012 
S Control DR 2147/2006 
T Control WC 11/1670/2012 
W Control WC 11/720/2012 
X Control WC 11/1628/2012 
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Ethics approval Letter 
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Master data sheets showing MCT levels, Sample Identification letter and cell counts per field. 
 
N.B. Should it be required, a CD-ROM with the full size excel spreadsheets is available, alternatively 
the full size spreadsheets can be forwarded electronically. 
 
Key: Ana = Anaphylaxis sample; Con = Control sample; S.C.= Secondary Control sample 
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consideration by JFS, at the end of the six-month period, the interest of JFS in the 
manuscript automatically terminates.  
 
Upon acceptance for publication, manuscripts become the copyright property of AAFS.  
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references. Tables, figures and figure legends are uploaded as separate files on the 
Manuscript Central site. Figure legends should be included on a page separate from the 
figures themselves. If the Abstract is not typed directly into Manuscript Central please  
submit that as a separate upload.  
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All persons designated as authors should qualify for authorship. The order of authorship 
should be a joint decision of the coauthors. Each author should have participated sufficiently 
in the work to take public responsibility for the content.  
 
Authorship credit should be based only on substantial contributions to: a) conception and 
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important intellectual content, and on c) final approval of the version to be published. 
Conditions a), b) and c) must all be met. Participation solely in the acquisition of funding or 
the collection of data does not justify authorship. General  
supervision of the research group is not sufficient for authorship. Any part of an article  
critical to its main conclusions must be the responsibility of at least one author.  
 
JFS may require authors to justify the assignment of authorship. Increasingly, multi-center 
trials or work are attributed to a corporate author. All members of the group who are named 
as authors, either in the authorship position below the title or in a footnote, should fully meet 
the criteria for authorship as defined in the Uniform Requirements.  
Group members who do not meet these criteria should be listed, with their permission, under 
Acknowledgments or in an appendix (see Acknowledgments).  
 
Abstract and Keywords  
 
Abstracts should be no more than 150 words. This journal uses unstructured abstracts; 
however, the abstract should include the following – background, brief description of 
methods and results (give specific data and their statistical significance, if possible), and 
conclusions. Emphasize new and important aspects of the study or observations. The word 
ABSTRACT should be in capitals and bolded.  
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Authors should provide a minimum of six keywords that will assist indexers in cross-indexing 
the article and that may be published with the abstract. The first keyword must be Forensic 
Science; the second and subsequent words should assist abstracters in properly 
categorizing the work so that it will be found in journal article data bases by interested 
researchers. Use terms from the medical subject headings (MeSH) list of Index Medicus; if 
suitable MeSH terms are not yet available for recently introduced terms, present terms may 
be used. Frequently, the second keyword represents a subfield of forensic science, e.g. 
forensic anthropology, forensic pathology, or DNA typing. In  
manuscripts on DNA typing, every locus involved in the study should be listed as a separate 
keyword. Do not use abbreviations for keywords, e.g., polymerase chain reaction, not PCR; 




The text of observational and experimental articles is usually – but not necessarily – divided 
into sections with headings. JFS does not use an “Introduction” heading. The introductory 
text begins on the first text page. Other typical headings include Methods (or Materials and 
Methods), Results, and Discussion. Long articles may need subheadings within the sections 
to clarify their content, especially the Results and Discussion sections. Other types of 
articles, such as Case Reports are likely to need different headings and subheadings. 
Generally, avoid overuse of subheadings, especially  




In JFS, the text component of the manuscript begins with an introduction, but JFS does not 
use the “Introduction” heading. State the purpose of the article. Summarize the rationale for 
the study or observation. Give only strictly pertinent references, and do not review 
referenced articles extensively. Do not include data or conclusions from the work  




Describe your selection of the observational or experimental subjects (patients or laboratory 
animals, including controls) clearly. Identify the methods, apparatus (manufacturer's name 
and address in parentheses), and procedures in sufficient detail to allow other workers to 
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reproduce the results. Give references to established methods, including statistical methods 
(see below); provide references and brief descriptions for  
methods, that have been published but are not well known; describe new or  
substantially modified methods, give reasons for using them, and evaluate their limitations. 
Identify precisely all drugs and chemicals used, including generic name(s), dose(s), and 
route(s) of administration. Generally avoid the overuse of subheadings in the Methods 
section. Describe the methods and materials in narrative style, not in the style of a laboratory 




When reporting experiments on human subjects, indicate whether the procedures followed 
were in accordance with the ethical standards of the responsible committee on human 
experimentation (institutional or regional) or with the Helsinki Declaration of 1975, as revised 
in 1983. Do not use patient's names, initials, or hospital numbers,especially in illustrative 
material. When reporting experiments on animals, indicate whether the institution's or the 
National Research Council's guide for, or any national  




Describe statistical methods with enough detail to enable a knowledgeable reader with 
access to the original data to verify the reported results. When possible, quantify findings 
and present them with appropriate indicators of measurement error or uncertainty (such as 
confidence intervals). Avoid sole reliance on statistical hypothesis testing, such as the use of 
P values, which fails to convey important quantitative information. Discuss eligibility of 
experimental subjects. Give details about randomization. Describe the methods for and 
success of any blinding of observations.  
Report treatment complications. Give numbers of observations. Report losses to observation 
(such as dropouts from a clinical trial). References for study design and statistical methods 
should be to standard works (with pages stated) when possible rather than to papers in 
which the designs or methods were originally reported. Specify any general-use computer 
programs used.  
 
Put a general description of methods in the Methods section. When data are  
summarized in the Results section, specify the statistical methods used to analyze them. 
Restrict tables and figures to those needed to explain the argument of the paper and to 
P a g e  | 95 
assess its support. Use graphs as an alternative to tables with many entries; do not duplicate 
data in graphs and tables.  
 
Avoid non-technical uses of technical terms in statistics, such as "random" (which implies a 
randomizing device), "normal," "significant," "correlations," and "sample." Define statistical 




Present your results in logical sequence in the text, tables and illustrations. Do not repeat in 





Emphasize the new and important aspects of the study and the conclusions that follow from 
them. Do not repeat in detail data or other material given in the Introduction or the Results 
section. Include in the Discussion section the implications of the findings and their 
limitations, including implications for future research. Relate the observations to other 
relevant studies. Link the conclusions with the goals of the study, but avoid  
unqualified statements and conclusions not completely supported by your data. Avoid 
claiming priority and alluding to work that has not been completed. State new hypotheses 
when warranted, but clearly label them as such. Recommendations, when appropriate, may 
be included.  
 
In shorter manuscripts, such as those intended to be Technical Notes or Case Reports, the 
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contributions that need acknowledging but do not justify authorship, such as general support 
by a department chair or acknowledgments of technical help. Persons who have contributed 
intellectually to the paper but whose contributions do not justify authorship may be named 
and their function or contribution described – for example, "scientific adviser," "critical review 
of study proposal," "data collection," or "participation in clinical trial." Such persons must 
have given their permission to be named. The  
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name, because readers may infer their endorsement of the data and conclusions.  
Technical help should be acknowledged in a paragraph separate from those  
acknowledging other contributions.  
 
Acknowledgements of financial support should appear as footnotes to the title of the paper 




The heading of the reference list should be "References," and it should contain only 
published or in-press references cited by number in the text. Published abstracts (duly noted 
as being abstracts), printed manufacturers' protocols or instructions, and world wide web site 
URLs may be validly cited as references. Personal communications and submitted 
manuscripts are not valid references. Personal communications should be cited in the text, 
in parentheses, at the appropriate location. The References header  
should be bolded.  
 
Number references consecutively in the order in which they are first mentioned in the text. 
Identify references in tables, and legends by Arabic numerals. References cited only in 
tables or legends should be numbered in accordance with a sequence established by the 
first identification in the text of the particular table or figure. Within the text, tables or figures, 
cite references by Arabic numeral in parentheses. Within the reference list,  
number the references 1., 2., 3., etc.  
 
References in the reference list should be in accordance with Uniform Requirements - style 
of the examples given below. This style is based with slight modifications on the formats 
used by the U.S. National Library of Medicine in Index Medicus. The titles of journals should 
be abbreviated according to the style used in Index Medicus. Consult List of Journals 
Indexed in Index Medicus, published annually as a separate publication  
by the library and as a list in the January issue of Index Medicus.  
 
The references must be verified by the author(s) against the original documents.  
Examples of correct forms of references are given below.  
Articles in Journals  
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1. Standard journal article  
 
(List all authors, but if the number exceeds six, give six followed by et al.) You CH, Lee KY, 
Chey RY, Menguy R. Electrogastrographic study of patients with unexplained nausea, 
bloating and vomiting. Gastroenterology 1980 Aug;79(2):311-4.  
 
As an option, if a journal carries continuous pagination throughout a volume, the month and 
issue number may be omitted.  
 
You CH, Lee KY, Chey RY, Menguy R. Electrogastrographic study of patients with 
unexplained nausea, bloating and vomiting. Gastroenterology 1980;79:311-4.  
 
Goate AM, Haynes AR, Owen MJ, Farrall M, James LA, Lai LY et al. Predisposing locus for 
Alzheimer's disease on chromosome 21. Lancet 1989;1:352-5.  
 
2. Organization as author  
 
The Royal Marsden Hospital Bone-Marrow Transplantation Team.Failure of syngeneic bone-
marrow graft without preconditioning in post-hepatitis marrow aplasia. Lancet  
1977;2:742-4.  
 
3. No author given  
 
Coffee drinking and cancer of the pancreas [editorial]. BMJ 1981;283:628.  
 
4. Article not in English  
 
Massone L, Borghi S, Pestarino A, Piccini R, Gambini G. Localisations palmairespurpuriques 
de la dermatiteherpetiforme. Ann DermatolVenereol 1987;114:1545-7.  
 
5. Volume with supplement  
 
Magni F, Rossoni G, Berti F. BN-52021 protects guinea-pig from heart anaphylaxis. 
Pharmacol Res Commun 1988;20Suppl 5:75-8.  
 
6. Issue with supplement  
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Gardos G, Cole JO, Haskell D, Marby D, Paine SS, Moore R.The natural history of tardive 
dyskinesia. J ClinPsychopharmacol 1988;8(4 Suppl):31S-37S.  
 
7. Volume with part  
 
Hanly C. Metaphysics and innateness: a psychoanalytic perspective. Int J Psychoanal 
1988;69(Pt 3):389-99.  
 
8. Issue with part  
 
Edwards L, Meyskens F, Levine N. Effect of oral isotretinoin on dysplastic nevi. J Am 
AcadDermatol 1989;20(2 Pt 1):257-60.  
 
9. Issue with no volume  
 
Baumeister AA. Origins and control of stereotyped movements.Monogr Am 
AssocMentDefic1978;(3):353-84.  
 
10. No issue or volume  
 
Danoek K. Skiing in and through the history of medicine. Nord MedicinhistArsb 1982;86-100.  
 
11. Pagination in roman numerals  
 
Ronne Y. AnsvarsfallenBlodtransfusion till felpatient.Vardfacket 1989;13:XXXVI-XXVII.  
 
12. Type of article indicated as needed  
 
Spargo PM, Manners JM. DDAVP and open heart surgery [letter]. Anaesthesia 1989;44:363-
4.  
 
13. Article containing retraction  
Shishido A. Retraction notice.Effect of platinum compounds on murine lymphocyte 
mitogenesis [Retraction of Alsabti EA, Ghalib ON, Salem MN. In: Jpn J Med SciBiol 
1979;32:53-65]. Jpn J Med SciBiol 1980;33:235-7.  
 
14. Article retracted  
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Alsabti EA, Ghalib ON, Sale MN. Effect of platinum compounds on murine lymphocyte 
mitogenesis [Retracted by Shishido A. In: Jpn J Med SciBiol 1980;33:235-7]. Jpn J  
Med SciBiol 1979;32:53-65.  
 
15. Article containing comment  
 
Piccoli A, Bossatti A. Early steroid therapy in IgA neuropathy: still an open question 
[comment] Nephron 1989;51:289-91. Comment on: Nephron 1988;48:12-7.  
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